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Preterm birth (PTB) is a leading cause of mortality and disease burden globally;
however, determinants of human parturition remain largely uncharacterized, making
prediction and prevention of difficult. Genetic studies are one way in which we can
attempt to better understand this disorder.
We first sought to develop a model for the genetic influences on PTB to facilitate
gene discovery. Study of standard measures of familial aggregation, the sibling risk ratio
and the sibling-sibling odds ratio, and segregation analyses of gestational age, a
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quantitative proxy for preterm birth, lend support to a genetic component contributing to
birth timing, since preterm deliveries cluster in families and models in which
environmental factors alone contribute to gestational age are strongly rejected. Analyses
of gestational age attributed to the infant support a model in which mother’s genome
and/or maternally-inherited genes acting in the fetus are largely responsible for birth
timing.
We also aimed to discover specific genes associated with PTB by screening genes
selected based on an evolutionary-motivated filter, rather than known parturition
physiology. Because humans are born developmentally less mature than other mammals,
birth timing mechanisms may differ between humans and model organisms that have
been typically studied; as a result, we screened 150 genes, selected because of their rapid
evolution along the human lineage. A screen of over 8000 SNPs in 165 Finnish preterm
and 163 control mothers identified an enrichment of variants in FSHR associated with
PTB and prompted further study of the gene. Additionally, PLA2G4C, identified as the
gene with the most statistically significant evidence for rapid evolution that was also
included in a list of preterm birth candidate genes, was examined further. Three SNPs in
PLA2G4C and one SNP in FSHR were statistically significant across populations after
multiple testing corrections. Additional work to identify variants in these genes with
functional effects was also initiated, including comparisons of prostaglandin metabolite
levels among genotype classes for significantly associated SNPs in PLA2G4C and
sequencing of FSHR to identify functional coding variants. Together, these experiments
better characterize the nature of genetic influences on PTB and support the role of
PLA2G4C and FSHR in PTB.
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Chapter 1: Introduction*
Clinical aspects of preterm birth (PTB)
Human parturition typically occurs between 37-42 weeks of gestation, with 40
weeks being the most common time of delivery (Figure 1.1). Deliveries before 37 weeks
are designated as “preterm” births by the World Health Organization [1] and represent an
important public health concern. Approximately one-third of infant deaths are attributable
to prematurity [2]. Preterm infants also have an increased risk of serious health problems,
such as respiratory illness, blindness and cerebral palsy [3]. Moreover, the severity and
incidence of these problems worsen with decreasing gestational age [4].
A variety of subtypes of PTB can be described. For example, preterm births may
be spontaneous or medically indicated. For 20-30% preterm births, women are delivered
early to minimize complications from maternal conditions, like preeclampsia, or fetal
distress [4]. However, most preterm births result from spontaneous preterm labor or
preterm premature rupture of membranes (PPROM) [4]. Preterm labor or PPROM may
arise in response to various stimuli, such as damage to the placental unit, intrauterine
infection or changes in cervical length, but the mechanisms by which these processes are
initiated are unknown. Additionally, early births of multiple gestations, which are
generally delivered earlier than singletons, may occur by different mechanisms than
singleton PTB. Hence, considerable heterogeneity in etiology may exist among various
subgroups of PTB and warrants careful consideration of phenotype in studies of PTB.
PTB is common, with rates consistently rising in recent decades. In 2006, 12.8%
of births in the United States occurred before 37 weeks, a 21% increase since 1990 [5].
*

This chapter is adapted from: Plunkett J & Muglia LJ. (2008) Genetic Contributions to PTB:
Implications from Epidemiological and Genetic Association Studies. Ann Med., 40(3):167-95.
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While the recent rise in multiple births, which are generally delivered earlier than
singletons, contributes to this increase, the rate among singleton gestations has risen 13%
since 1990 and is now 11.1%. Among singleton PTB, late-preterm births (34-36 weeks)
account for all of the increase, with essentially no change in the rate of births <34 weeks
during this period. Importantly, cesarean-delivery rates have also increased since 1990,
such that medically-indicated PTB may represent a greater portion of the increase in
overall PTB rate. Consequently, distinguishing spontaneous from medically-indicated
PTB may be important in identifying risk factors for this condition.
Of note, rates differ among racial groups. Blacks experience approximately twice
the rate of PTB than that of Whites. The highest PTB rates are observed when both
parents are Black and remain higher when one parent is Black, whether that parent is the
mother or father [6; 7]. According to a study by Goldenberg and colleagues [8], these
racial disparities are not explained entirely by measured medical and environmental risk
factors, such as smoking, hypertension, education level or socioeconomic status,
suggesting that other differences among races, such as genetic ancestry, contribute to the
disorder. As a result, careful consideration of important differences in social, cultural and
biological factors among races also are important in studies of PTB risk.
Motivation for studying genetics
While a number of risk factors have been identified, accurate prediction and
prevention of PTB are difficult [4]. For example, biomarkers, such as serum protein
concentrations of IL-6, IL-8, TNF or relaxin, while strong predictors of PTB, may not
be useful in large low-risk populations [9]. One problem may be that such markers vary
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over time or among individuals, making it difficult to determine levels at which risk for
PTB is increased.
In contrast, genetic factors are stable over time and therefore may be better
predictors of risk. As a result, genetic studies may identify markers which more
accurately predict PTB than currently known risk factors. Genetic studies may also
identify novel proteins and/or pathways involved in the disorder. This new information
will augment our general understanding of parturition and provide new targets for drug
therapies, potentially improving both prevention and treatment of PTB.

Evidence for genetic influences on birth timing
Birth timing across pregnancies in the same woman
A wealth of evidence suggests that genetics are important in birth timing. For
example, both preterm and postterm births tend to recur in mothers [10-15]. Moreover,
the most likely age for a recurrent PTB is same week as the first PTB [12; 16; 17],
suggesting that factors that are stable over time, such as genetics, affect birth timing.
Birth timing trends among family members
Familial trends for birth timing also suggest that genetics influence this trait.
Women who are born preterm are more likely to have a preterm delivery themselves [18],
indicating that mothers and their daughters share risk. Sisters of women who have had a
preterm delivery also have an increased risk for preterm delivery [15]. Due to the nature
of family studies, environmental factors shared between mothers and daughters or
between sisters cannot be untangled from genetic influences. As a result, it is difficult to
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determine the relative importance of genetic versus environmental factors from these
studies alone.
Partitioning variance in birth timing into genetic versus environmental components
In contrast to family studies, twin studies measure the relative importance of
genes in overall trait variance within a population. By comparing concordance rates
between monozygotic and dizygotic twins, which share 100% and approximately 50% of
their genes, respectively, one can model the genetic and environmental factors that
influence a trait. Such studies indicate that genes account for about 30% of variation in
preterm delivery [19; 20] and child’s gestational age as continuous trait [19; 21], when
the mother is considered the proband of a delivery.
A similar method was used to estimate the influence of maternal and fetal genetic
factors by Lunde and colleagues [22]. Comparing concordance rates among full and half
siblings for gestation age, the authors estimated that 11% of variation for this trait is due
to fetal genetic factors and 14% of variation is due to maternal genetic factors [22]. Such
comparisons use the degree of genetic relatedness (on average 50% for full siblings and
25% for half siblings) and trait concordance to estimate the relative importance of genetic
versus environmental factors. Because siblings that are not monozygotic twins display
some variability in their percent genetic identity and may differ in important dominance
or interactive genetic effects, these estimates are more difficult to make using non-twin
siblings. Despite the limitations in estimating the heritability, each study suggests that
genetics play an important role in PTB.
Another approach to separating genetic and environmental factors is the
coefficient of kinship. This measure depicts the degree of genetic relatedness within a
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population. Ward and colleagues [23] used this measure to examine genetic influences on
PTB in a Utah population. The Utah population from which the families were drawn was
established by 10,000 people who moved to the state to establish the Mormon religion
[23]. Because Mormons are discouraged from using alcohol or tobacco and have low
rates of substance abuse and sexually-transmitted diseases, this population may represent
individuals with relatively few environmental risk factors for PTB [23]. As a result,
detecting genetic effects may be easier in this cohort of Utah preterm families. In this
study, Ward and colleagues found that families with preterm deliveries had a
significantly lower coefficient of kinship than controls [23], indicating that these families
are more closely genetically-related than control families. This evidence suggests that the
increased rate of PTB in these families can be explained by genetic factors. It is important
to note that the authors of this study did not report the relative abundance of any
environmental risk factors for PTB in the two populations. It is possible that one or more
important environmental risk factors differ between these groups, in addition to genetic
relatedness. Hence, the results of Ward et al. [23] support the significance of genetics in
PTB, but do not address their relative importance compared to known environmental risk
factors.
Mendelian disorders
Certain Mendelian disorders are associated with PTB, further supporting genetic
effects on birth timing. Ehlers-Danlos Syndrome (EDS) represents a diverse group of
Mendelian disorders affecting connective tissue, primarily inherited in an autosomal
dominant manner [24]. Women with vascular EDS have an increased risk of delivering
preterm, primarily due to PPROM [24]. Since this disorder is inherited in an autosomal
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dominant pattern, there is a 50% chance the fetus has inherited the disorder, making it
less clear whether the mother’s or infant’s genome contributes to the increase in PPROM
risk.
Possible role of fetal genome in birth timing
Several lines of evidence further suggest that fetal genetic effects may influence
birth timing. First, fetal genes that are paternally imprinted mainly control placental and
fetal membrane growth [25]. Because the placenta and fetal membranes likely play a role
in PTB, fetal genes controlling these tissues may also contribute. Additionally, several
studies suggest that paternity affects risk for the disorder. For example, several studies
indicate that partner changes between pregnancies reduced risk of PTB [26; 27];
however, changes in paternity may reflect association with long interpregnancy intervals
rather than paternity effects per se. Paternal race also has been associated with PTB risk
[6; 7], suggesting that fetal race may influence birth timing. However, father’s family
history of PTB has been shown to have only a weak association with risk. While an early
study of a Norwegian birth registry demonstrated a correlation between fathers’ and
children’s gestational ages [28], a more recent and extensive study of this registry
suggested fathers contributed little to no risk to preterm delivery risk [29]. Similarly,
recent studies [21; 30] suggested that paternal genetics contributed little to gestational
age, but could not refute the possible role of maternally-inherited genes expressed in the
fetus. Hence, while paternally-inherited genes may contribute little to PTB or other
disorders, maternally-inherited genes expressed in the fetus may still be important.
Together, these data suggests that the fetal genome may contribute to birth timing,
motivating further study defining the infant as the proband.
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Complexity of genetic effects on birth timing
There is increasing evidence that PTB can be conceptualized as a common,
complex disorder. In contrast to Mendelian disorders in which alterations of a single gene
can lead to disease, complex diseases are influenced by a variety of factors, none
necessary and sufficient to cause the disorder itself. As a result, there is not a direct
relationship between genotypes and phenotypes [31]. These disorders likely depend on a
number of interacting factors, including genetic, epigenetic and environmental risk
factors[31]. Modeling procedures used by twin studies suggest that additive genetic
factors and environmental risk factors that are not shared among siblings both influence
PTB [19; 20; 32]. Additionally, interactions between genes [33; 34] have been associated
with PTB risk. Several studies suggest that gene-environment interactions, such as
interactions between inflammatory gene risk alleles and bacterial infections [35-37], also
influence the disorder. Together, these studies imply that the etiology of PTB likely
involves genetic as well as environmental factors in complex interactions.
In addition to the complexity of genetic effects described above, several issues
complicate how investigators think about the disorder. As mentioned above, it is not clear
whether the mother or infant from a preterm delivery should be considered the proband.
As a result, it is not clear which individual’s DNA should be interrogated. Additionally,
preterm delivery as a trait can be thought of in two ways. First, PTB can be thought of as
discrete, resulting from genetic factors that lead to either term or early delivery.
Alternatively, gestational age can be thought of as a quantitative trait, with preterm ages
as extremely low values; hence, genetic effects may be quantitative trait loci (QTLs) that
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influence the value of gestational age in both term and preterm deliveries. As disease
models shape how one approaches identifying genes, it is important to consider the
uncertainty about how to conceptualize PTB when evaluating various approaches taken
to study this trait.

Identifying specific genes associated with PTB
Functional candidate gene studies have identified few genes consistently associated
with PTB
Candidate genes in a variety of pathways believed to be important in parturition
have been tested with mixed results (summary in Table 1.1). Few positive association
findings for PTB have been consistent. To illustrate, for TNF, the most extensively
studied gene, 11 studies report major effects of the gene[34; 36; 38-46]; yet, 13 others
report no major effects of the gene [35; 47-56], including a meta-analysis of 7 studies
[51]. Similarly, IL1RN was associated in 4 studies [57-60], but not in another 6 [39; 46;
53; 56; 61]. One possible explanation may be that some polymorphisms are significant
only in the context of a particular environmental factor, such as infection. For example,
IL6 has been associated in 2 studies without considering environmental influences [62;
63], associated in another 2 studies only in the context of infection [35; 37], associated in
another study only in interaction with other genes [41], and not associated in an
additional 10 studies [34; 39; 42; 46; 53; 54; 56; 64; 65].
A number of problems in previous studies’ design may limit their ability to detect
true genetic effects. Most of these studies have been underpowered, because of small
sample sizes and/or incomplete sampling of genetic variation in a gene of interest.
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Phenotypic heterogeneity also may confound many studies’ results, as most consist of
mothers and/or children collected using a variety of phenotype definitions that may have
different etiologies. In addition, genetic etiologies may differ across ethnic groups, since
pregnancies in which either the mother or father is Black are at increased risk for preterm
delivery, regardless of which parent is Black; however, few studies have included
analyses separately by race or attempted to correct for possible population substructure,
further questioning the validity of many genes associated to date. Moreover, no genetic
model has been identified for PTB to suggest what nature of genetic effects is expected,
limiting investigators’ ability to appropriately design such studies. This proposal
considers such issues to better identify PTB genes.
Alternative approaches
A variety of alternative genetic approaches may be undertaken to identify specific
genes involved in PTB. For example, unbiased genome-wide screens, such as the screen
conducted on a Danish cohort as part of the National Institutes of Health Gene
Environment Association Studies (GENEVA) program, may identify novel genes and
pathways. Additionally, non-additive genetic effects, such as copy number or structural
variation, may be important avenues for future research. Such approaches may enable
investigators to identify novel genes and pathways involved in birth timing with
important clinical applications.

Objectives of dissertation
The etiology of PTB is complex and likely involves both genetic and
environmental risk factors. A variety of evidence supports genetic influences on PTB, yet
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few specific genes have been associated with PTB. Developing a model for the genetic
influences on PTB may facilitate gene discovery. As little work had been done to
systematically identify a genetic model for PTB, we used sibling risk estimates and
segregation analyses to identify one. Another method to facilitate discovery of specific
genes associated with PTB is using a priori methods. Using information from
comparative genomic studies, we conducted a screen of genes minimally biased by our
current understanding of parturition to identify novel PTB genes. In order to validate our
findings, we replicated genes identified in this screen in additional populations. Of note,
genes encoding the follicle-stimulating hormone receptor, FSHR, and a phospholipase,
PLA2G4C, showed evidence of association across populations and was investigated
further. Together, these experiments better characterize the nature of genetic influences
on PTB and provide evidence for novel genes involved in this disorder.
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Human parturition typically occurs between 37-42 weeks of gestation, with 40 weeks being the most common time of delivery.

Figure 1.1: Birth timing in Missouri (1978-1997).

Table 1.1: Summary of candidate gene association studies’ findings as of May 2010.
Gene
Symbol

Gene Name

ABCA1
ACE
ADD1
ADH1B
ADH1C
ADRB2
AGT
AGTR1
ALOX5AP
ANXA5
APOA1
APOA4
APOA5
APOB
APOC2
APOC3
APOE
BHMT
CBS
CCL2
CCL3
CCL8
CD14
CETP
COL1A1
COL1A2
COL3A1
COL5A1
COL5A2
CRH
CRHBP
CRHR1
CRHR2
CRP
CSF3
CTGF
CTLA4
CYP19A1

ATP-binding cassette, sub-family A, member 1
angiotensin I converting enzyme 1
adducin 1 (alpha)
alcohol dehydrogenase 1B
alcohol dehydrogenase 1c
adrenergic, beta-2, receptor, surface
angiotensinogen
angiotensin II receptor, type 1
arachidonate 5-lipoxygenase-activating protein
annexin A5
apolipoprotein A-I
apolipoprotein A-4
apolipoprotein A-5
apolipoprotein B
apolipoprotein C2
apolipoprotein C3
apolipoprotein E
betaine-homocysteine methyltransferase
cystathionine-beta-synthase
chemokine (C-C motif) ligand 2
chemokine (C-C motif) ligand 3
chemokine (C-C motif) ligand 8
monocyte differentiation antigen CD14
cholesteryl ester transfer protein, plasma
collagen, type I, alpha 1
collagen, type I, alpha 2
collagen, type 3, alpha 1
collagen, type 5, alpha 1
collagen, type 5, alpha 2
corticotropin releasing hormone
corticotropin releasing hormone binding protein
corticotropin releasing hormone receptor 1
corticotropin releasing hormone receptor 2
C-reactive protein, pentraxin-related
colony stimulating factor 3
connective tissue growth factor
cytotoxic T-lymphocyte-associated protein 4
cytochrome P450, family 19, subfamily A,
polypeptide 1
cytochrome P450, family 1, subfamily A,

CYP1A1

12

Number
of
Studies
1
7
2
4
5
8
3
2
1
1
1
1
1
1
1
1
1
1
5
4
4
4
5
1
3
3
3
4
4
4
5
4
4
4
1
1
4
4

Studies reporting
positive findings

7

2

0
1
0
0
0
3
2
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
1
0

CYP2C19
CYP2D6
CYP2E1
CYP3A4
DHCR24
DHCR7
DHFR
DRD2
EDN2
PROCR
EPHX1
EPHX2
F13A1
F2
F5
F7
FAS
FASLG
FGB
FLT1
GNB3
GSTM1
GSTP1
GSTT1
GSTT2
HMGCR
HSD11B1
HSD17B7
HSPA14
HSPA1A
HSPA1B
HSPA1L
HSPA4
HSPA6
ICAM1
ICAM3
IFNG
IFNGR1

polypeptide 1
cytochrome P450, family 2, subfamily C,
polypeptide 19
cytochrome P450, family 2, subfamily D,
polypeptide 6
cytochrome P450, family 2, subfamily E,
polypeptide 1
cytochrome P450, family 3, subfamily A,
polypeptide 4
24-dehydrocholesterol reductase
7-dehydrocholesterol reductase
dihydrofolate reductase
dopamine receptor D2
endothelin 2
protein C receptor, endothelial (EPCR)
epoxide hydrolase 1, microsomal (xenobiotic)
epoxide hydrolase 2, microsomal (xenobiotic)
coagulation factor XIII, A1 polypeptide
coagulation factor II (thrombin)
coagulation factor V
coagulation factor VII
Fas
Fas ligand
fibrinogen beta chain
fms-related tyrosine kinase 1
guanine nucleotide binding protein, beta
polypeptide 3
glutathione S-transferase mu 1
glutathione S-transferase pi 1
glutathione S-transferase theta 1
glutathione S-transferase theta 2
3-hydroxy-3-methylglutaryl-Coenzyme A
reductase
hydroxysteroid (11-beta) dehydrogenase 1
hydroxysteroid (17-beta) dehydrogenase 7
heat shock 70kDa protein 14
heat shock 70kDa protein 1A
heat shock 70kDa protein 1B
heat shock 70kDa protein 1-like
heat shock 70kDa protein 4
heat shock 70kDa protein 6
intercellular adhesion molecule 1
intercellular adhesion molecule 3
interferon, gamma
interferon, gamma receptor 1
13

1

0

4

0

2

0

1

0

1
1
4
1
4
1
5
4
1
9
12
7
4
4
2
1
1

0
0
0
0
0
0
0
0
0
0
4
1
0
0
0
0
0

4
5
5
4
1

2
0
2
0
1

4
4
4
4
4
4
4
4
2
1
6
1

0
0
0
0
0
1
0
0
1
0
2
0

IGF1
IGFBP3
IL10
IL10RA
IL10RB
IL11
IL12A
IL13
IL15
IL18
IL1A
IL1B
IL1R1
IL1R2
IL1RAP
IL1RN
IL2
IL2RA
IL2RB
IL4
IL4R
IL5
IL6
IL6R
IL8
IL8RA
ITGA2
ITGB3
KL
LCAT
LDLR
LIPC
LNPEP
LOXL1
LPL
LST1
LTA
MASP2
MBL2
MMP1
MMP2
MMP3
MMP8
MMP9
MTHFD1

insulin-like growth factor 1
insulin-like growth factor binding protein 3
interleukin 10
interleukin 10 receptor, alpha
interleukin 10 receptor, beta
interleukin 11
interleukin 12A
interleukin 13
interleukin 15
interleukin 18
interleukin 1, alpha
interleukin 1, beta
interleukin 1 receptor, type I
interleukin 1 receptor, type 2
interleukin 1 receptor accessory protein
interleukin 1 receptor antagonist
interleukin 2
interleukin 2 receptor, alpha
interleukin 2 receptor, beta
interleukin 4
interleukin 4 receptor
interleukin 5
interleukin 6
interleukin 6 receptor
interleukin 8
interleukin 8 receptor alpha
integrin, alpha 2
integrin, beta 3
Klotho
lecithin-cholesterol acyltransferase
LDL receptor
lipase, hepatic
leucyl/cystinyl aminopeptidase
lysyl oxidase-like 1
lipoprotein lipase
leukocyte specific transcript 1
lymphotoxin alpha
mannan-binding lectin serine peptidase 2
mannose-binding lectin 2, soluble
matrix metallopeptidase 1
matrix metallopeptidase 2
matrix metallopeptidase 3
matrix metallopeptidase 8
matrix metallopeptidase 9
methylenetetrahydrofolate dehydrogenase
14

4
4
9
5
4
1
1
5
4
5
8
9
5
5
4
10
6
4
4
8
4
4
15
7
7
4
1
1
4
1
1
1
1
1
1
4
5
1
10
5
4
5
4
5
4

0
0
2
1
0
0
0
1
1
0
1
1
0
1
0
4
1
1
1
3
0
1
5
3
0
0
0
0
1
0
0
0
0
0
0
0
1
0
6
1
1
0
0
2
0

MTHFR
MTR
MTRR
NAT1
NAT2
NFKB1
NFKB2
NFKBIA
NFKBIB
NFKBIE
NOD2
NOD2/CAR
D15
NOS2A
NOS3
NPPA
NQO1
NR3C1
OPRM1
OXT
OXTR
PAFAH1B1
PAFAH1B2
PDE4D
PGEA1
PGR
PGRMC1
PGRMC2
PLA2G4A
PLAT
POMC
PON1
PON2
PPARG

5,10-methylenetetrahydrofolate reductase
5-methyltetrahydrofolate-homocysteine
methyltransferase
5-methyltetrahydrofolate-homocysteine
methyltransferase reductase
N-acetyltransferase 1
N-acetyltransferase 2
nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1
nuclear factor of kappa light polypeptide gene
enhancer in B-cells 2
nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, alpha
nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, beta
nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, epsilon
nucleotide-binding oligomerization domain
containing 2
nucleotide-binding oligomerization domain
containing 2
nitric oxide synthase 2, inducible
nucleotide-binding oligomerization domain
containing 3
natriuretic peptide precursor A
NAD(P)H dehydrogenase, quinone 1
glucocorticoid receptor
opioid receptor, mu 1
oxytocin
oxytocin receptor
platelet-activating factor acetylhydrolase,
isoform Ib, subunit 1
platelet-activating factor acetylhydrolase,
isoform Ib, subunit 2
phosphodiesterase 4D, cAMP-specific
chibby homolog 1
progesterone receptor
progesterone receptor membrane component 1
progesterone receptor membrane component 2
phospholipase A2, group IVA
plasminogen activator, tissue
proopiomelanocortin
paraoxonase 1
paraoxonase 2
peroxisome proliferator-activated receptor
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11
1

0
0

2

1

5
6
4

0
0
0

4

0

4

0

4

0

4

0

2

1

4

0

2
7

2
1

1
1
4
1
1
1
4

0
0
0
1
0
1
0

4

0

1
4
9
4
4
4
6
4
7
6
1

0
0
1
0
0
0
2
0
3
2
1

PRKCA
PROC
PTCRA
PTGER2
PTGER3
PTGES
PTGFR
PTGS1
PTGS2
PTPN22
REN
RFC1
RLN1
RLN2
RLN3
SCGB1A1
SCNN1A
SELE
SERPINB2
SERPINE1
SERPINH1
SFTPC
SFTPD
SHMT1
SLC23A1
SLC23A2
SLC6A4
TCN2
TFPI
TGFA
TGFB
TGFB1
THBD
TIMP3
TIMP4
TLR10
TLR2
TLR3
TLR4

gamma
protein kinase C, alpha
protein C
pre T-cell antigen receptor alpha
prostaglandin E receptor 2
prostaglandin E receptor 3
prostaglandin E synthase
prostaglandin F receptor
prostaglandin G/H synthase (cyclooxygenase)
prostaglandin-endoperoxide synthase 2
protein tyrosine phosphatase, non-receptor type
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renin
replication factor C (activator 1) 1
Relaxin 1
Relaxin 2
Relaxin 3
secretoglobin, family 1A, member 1
(uteroglobin)
sodium channel, nonvoltage-gated 1 alpha
selectin E
serpin peptidase inhibitor, clade B (ovalbumin),
member 2
serpin peptidase inhibitor, clade E, member 1
serpin peptidase inhibitor, clade H, member 1
(collagen binding protein 1)
Surfactant protein C
Surfactant protein D
serine hydroxymethyltransferase 1
solute carrier family 23 (nucleobase
transporters), member 1
solute carrier family 23, member 2
solute carrier family 6, member 4
transcobalamin II
tissue factor pathway inhibitor
transforming growth factor, alpha
transforming growth factor, beta
transforming growth factor, beta 1
thrombomodulin
TIMP metallopeptidase inhibitor 3
TIMP metallopeptidase inhibitor 4
toll-like receptor 10
toll-like receptor 2
toll-like receptor 3
toll-like receptor 4
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1
1
4
5
4
5
5
4
4
4

1
0
0
1
2
0
0
0
0
0

1
1
1
1
1
4

0
0
0
0
0
0

1
2
1

0
0
0

6
6

1
2

2
1
1
5

0
0
1
0

1
4
4
1
1
1
6
1
4
4
1
6
4
9

1
0
0
0
0
0
0
1
0
0
1
1
0
2

TLR7
TLR8
TLR9
TNF
TNFR1
TNFR2
TNFRSF1A
TNFRSF1B
TNFRSF6
TRAF2
TREM1
TSHR
UGT1A1
VEGF

toll-like receptor 7
toll-like receptor 8
toll-like receptor 9
tumor necrosis factor
tumor necrosis factor receptor 1
tumor necrosis factor receptor 2
tumor necrosis factor receptor superfamily,
member 1A
tumor necrosis factor receptor superfamily,
member 1B
tumor necrosis factor receptor superfamily,
member 6b, decoy
TNF receptor-associated factor 2
triggering receptor expressed on myeloid cells 1
thyroid stimulating hormone receptor
UDP glucuronosyltransferase 1 family,
polypeptide A1
vascular endothelial growth factor A
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24
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0
0
0
11
4
2
0

4

0

2

1

4
4
4
4

0
1
0
0
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Chapter 2: Increased risk to siblings of preterm infants suggests genetic factors may
influence PTB†

Abstract
Adverse pregnancy outcomes, such as PTB, PPROM, placental abruption, and
preeclampsia, are common and contribute to spontaneous and medically-indicated
preterm deliveries, with acute and long-term complications for both the mother and
infant. Etiologies underlying such adverse outcomes are not well understood. As maternal
and fetal genetic factors may influence these outcomes, we estimated the magnitude of
familial aggregation as one index of possible heritable contributions. Using the Missouri
Department of Health’s maternally-linked birth certificate database, we performed a
retrospective population-based cohort study of births (1989-1997), designating an
individual born from an affected pregnancy as the proband for each outcome studied. We
estimated the increased risk to siblings compared to the population risk, using the sibling
risk ratio, s, and sibling-sibling odds ratio (sib-sib OR), for the adverse pregnancy
outcomes of PTB, PPROM, placental abruption, and preeclampsia. Risk to siblings of an
affected individual was elevated above the population prevalence of a given disorder, as
indicated by

S( S

(95% CI): 4.3 (4.0-4.6), 8.2 (6.5-9.9), 4.0 (2.6-5.3), and 4.5 (4.4-4.8),

for PTB, PPROM, placental abruption, and preeclampsia, respectively). Risk to siblings
of an affected individual was similarly elevated above that of siblings of unaffected
individuals, as indicated by the sib-sib OR (sib-sib OR adjusted for known risk factors

†

This chapter is adapted from: Plunkett J, et al. (2008) Population-based estimate of sibling risk
for adverse pregnancy outcomes. BMC Genetics, 9:44.
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(95% CI): 4.2 (3.9-4.5), 9.6 (7.6-12.2), 3.8 (2.6-5.5), 8.1 (7.5-8.8) for PTB, PPROM,
placental abruption, and preeclampsia, respectively). These results suggest that the
adverse pregnancy outcomes of PTB, PPROM, placental abruption, and preeclampsia
aggregate in families, which may be explained in part by genetics.
Introduction
In the United States, 12.7% of births occur preterm (<37 weeks) [66],
approximately one-fourth of which occur due to PPROM [67]. Preeclampsia, high blood
pressure and fluid retention in pregnancy, and placental abruption, early detachment of
the placenta from the uterus, affect approximately 7% [68] and 1% [69] of all
pregnancies, respectively. While many pregnancies share more than one of these
complications, together they affect a significant portion of pregnancies and represent the
most common reasons for early delivery. Moreover, adverse pregnancy outcomes are
important causes of perinatal morbidity and mortality. For example, placental abruption,
while uncommon, accounts for 12% of all perinatal deaths [25]. The incidence of PTB
[66] and placental abruption [25] have increased over recent decades, further motivating
additional study to understand susceptibility factors which contribute to these outcomes.
Prediction and prevention of these adverse outcomes is difficult. Etiologies
underlying PTB, PPROM, placental abruption and preeclampsia are not well understood.
Genetic studies are one way in which we can attempt to better understand these disorders.
Such studies may identify genetic markers that can predict one’s risk for a particular
pregnancy outcome. Genetic studies may also identify novel proteins and/or pathways
involved in the disorder.
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Both maternal and fetal genetic factors may influence adverse pregnancy
outcomes. Evidence suggests that maternal genetic factors contribute to PTB [70; 71],
PPROM [71-73], placental abruption [74; 75] and preeclampsia [76-79]. In contrast, fetal
effects on these outcomes have not been well studied. Several lines of evidence suggest
that fetal genetic effects may influence adverse pregnancy outcomes. First, fetal genes
that are paternally imprinted mainly control placental and fetal membrane growth [25].
Because the placenta and fetal membranes likely play a role in adverse pregnancy
outcomes, fetal genes controlling these tissues may also contribute. Additionally,
heritability studies, which estimate the relative portion of population variation in a trait
due to genetics, suggest that PTB [22] and preeclampsia [80] are influenced in part by
fetal genetic factors. Lastly, several studies suggest that paternity affects risk for PTB and
preeclampsia. For example, several studies indicate that partner changes between
pregnancies reduce risk of PTB [26; 27] and preeclampsia [80-83]. Changes in paternity
may reflect association with long interpregnancy intervals rather than paternity effects
per se; however, for preeclampsia [78; 84], fathers’ family history affects risk for the
disorder in their partners’ pregnancies. For PTB, father’s family history has been shown
to have only a weak association with risk. While an early study of a Norway birth registry
demonstrated a correlation between father and children’s gestational ages [28], a more
recent and extensive study of this registry suggested fathers contributed little to no risk to
preterm delivery risk [29]. Also, paternal race has been associated with PTB risk [6; 7].
Together, this data suggests that paternal genes expressed in the fetus may contribute to
these disorders, motivating study of maternal-fetal influences, assessed by defining the
infant as the proband, in addition to influences that are maternal-specific.
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While multiple lines of evidence suggest the importance of genetic contributors in
adverse pregnancy outcomes, observing clustering of such outcomes in families is
necessary to assert genetic influences on a disorder. A disorder that does not aggregate in
families is unlikely to be influenced by inherited factors. Hence, detecting an increased
risk for a disorder among siblings or other family members of an individual born from a
pregnancy affected by the same adverse outcome would further support genetic
influences on these conditions. However, familial aggregation is not sufficient to claim
genetic influences on a disorder. Since family members share both genes and
environment, any similarities seen in families may be explained by genetic or shared
environmental factors (such as in utero environment) or by their interaction.
Two standard measures of familial aggregation are increase in risk to siblings of
affected individuals, compared to the population risk for the disorder, the sibling risk
ratio, s [85], and compared to siblings of unaffected individuals, the sibling-sibling odds
ratio (sib-sib OR) [86]. These measures have been estimated for a variety of disorders,
ranging from single locus Mendelian disorders, such as cystic fibrosis [87], to complex
disorders, including hypertension [88], type 2 diabetes [89], and myopia [90; 91]. These
familial aggregation measures have been incompletely documented in pregnancy
outcomes. When considering mother as the affected individual, investigators have
reported increased risk among first-degree relatives of women affected with PTB [15;
18], placental abruption [75] and preeclampsia [78; 92]; however, few of these studies
have scaled the increase in risk among relatives by the population prevalence for a given
pregnancy outcome (placental abruption [75] , preeclampsia [92] ), as done to calculate
s. Maternal recurrence risk, similar in calculation to the sib-sib OR, has previously been
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reported for these disorders [73; 93-98]. Yet, only one study of PTB and PPROM [73]
scaled maternal recurrence relative to population prevalence of the disorder and did not
consider this measure as an indication of familial aggregation. s and sib-sib OR,
defining the infant of an affected pregnancy as proband, have not been reported for these
disorders. Estimating s, in which the increased risk for a disorder is scaled by population
prevalence, is particularly important, as population prevalence can vary by race. While
there may be a significant increase in risk among siblings or a significant maternal
recurrence risk, such a risk may reflect high population prevalence, rather than familial
effects, per se. As a result, calculating s may lead to different conclusions that those
made by previous reports of maternal recurrence risk. Since individual demographic
factors, such as socioeconomic status or body mass index, may also contribute to risk, we
calculate sib-sib OR adjusted for important medical and environmental risk factors to
assess to what extent genetic effects may account for familial aggregation.
In order to test whether genetic effects may influence these outcomes, our
analyses define the infant of an affected pregnancy as the proband. We estimate s and
sib-sib OR to determine whether each outcome clusters in families.
Results
Preterm birth. The population risks for PTB at <35 gestational weeks were
estimated as 3.6%, 2.8%, and 7.8%, in all races, Whites and Blacks, respectively. Among
second-born siblings in the sibling subcohort whose older sibling was affected, rates of
PTB for all races, Whites and Blacks, respectively, were used to estimate the sibling risk
(see Table 2.1).

S

and its 95% CI were 4.3 (4.0-4.6), 4.4 (4.0-4.7), and 2.8 (2.6-3.1) for
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all races, Whites, and Blacks, respectively, indicating a significant increase in risk to
siblings of PTB patients compared to the population.
Individuals whose older sibling was affected by PTB were also at significantly
higher risk compared to individuals whose older sibling was unaffected (see Table 2.1).
This increase in risk persisted after adjusting for known risk factors. Adjusted OR with
95% CI were 4.2 (3.9-4.5), 5.1 (4.6-5.7), and 3.3 (2.9-3.7) for all races, Whites and
Blacks, respectively.
PPROM. The population risks for PPROM were estimated as 0.8%, 0.6% and
1.9%, in all races, Whites and Blacks, respectively. Among second siblings in the
matched sibling sub-cohort whose older sibling was affected, rates of PPROM were used
to estimate sibling risk (see Table 2.2).

S

and its 95% confidence interval were 8.19

(6.50-9.88), 6.75 (4.59-8.91), and 6.40 (4.66-8.14) for all races, Whites, and Blacks,
respectively, indicating a significant increase in risk to siblings of PPROM patients
compared to the population.
Individuals whose older sibling was affected by PPROM were also at
significantly higher risk compared to individuals whose older sibling was unaffected (see
Table 2.2). This increase in risk persisted after adjusting for known risk factors. Adjusted
OR with 95% CI were 9.6 (7.6-12.2), 8.5 (6.0-12.1), and 8.9 (6.4-12.5) for all races,
Whites and Blacks, respectively.
Placental Abruption. Population rates of placental abruption were estimated as
0.8%, 0.7%, 1.0%, in all races, Whites and Blacks respectively. Among second siblings
in the matched sibling sub-cohort whose older sibling was affected, rates of placental
abruption were used to estimate risk to siblings (see Table 2.3).
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S

and its 95%

confidence interval were 3.95 (2.63-5.27) and 4.93 (3.18-6.68), for all races and Whites,
respectively, indicating a significant increase in risk to siblings of placental abruption
patients compared to the population.
We found that individuals whose older sibling was affected by placental abruption
were also at significantly higher risk compared to individuals whose older sibling was
unaffected (see Table 2.3). This increase in risk persisted after adjusting for known risk
factors. Adjusted OR with 95% CI: 3.8 (2.6-5.5) and 5.0 (3.4-7.4) for all races and
Whites, respectively.
Blacks did not show a significant increase in risk to siblings of placental
abruption births either compared to the population ( S= 1.64 (0.04-3.24)) or compared to
siblings of births unaffected by this disorder (unadjusted OR: 1.4 (0.5-3.7), adjusted OR:
1.2 (0.4-3.9)).
Preeclampsia. Population rates of preeclampsia were estimated as 3.2%, 3.1%,
and 4.1%, in all races, Whites and Blacks, respectively. Among second siblings in the
matched sibling sub-cohort whose older sibling was affected, rates of preeclampsia were
used to calculate sibling risk (see Table 2.4).

S

and its 95% confidence interval were

4.51 (4.24-4.78), 4.52 (4.21-4.83), and 4.11 (3.59-4.63) for all races, Whites, and Blacks,
respectively.
We found that individuals whose older sibling was affected by preeclampsia were
also at significantly higher risk compared to individuals whose older sibling was
unaffected (see Table 2.4). This increase in risk persisted after adjusting for known risk
factors. Adjusted OR with 95% CI were 8.1 (7.5-8.8), 9.0 (8.2-9.8), and 5.8 (4.9-7.0) for
all races, Whites and Blacks, respectively.
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Discussion
We hypothesized that siblings of individuals who were products of pregnancies
affected by one of several adverse outcomes, PTB, PPROM, placental abruption and preeclampsia, would be at increased risk for the same outcome. s and sib-sib OR values
significantly greater than one indicate that risk to siblings of adverse pregnancy outcome
births is elevated compared to the population rate and to the rate in siblings of unaffected
individuals, respectively. None of the 95% CI for s or sib-sib OR values overlap with
one, with the exception of placental abruption in Blacks. The lack of evidence for familial
aggregation of placental abruption in Blacks may be explained by the rarity of the event
and the relatively small racial subgroup (see Table 2.3). These data suggest that genetic
and/or environmental risk factors shared among siblings affect these disorders.
Estimates of sib-sib OR are consistent with previous studies of maternal
recurrence risk in the Missouri birth certificate database [93; 94], and of maternal
recurrence risk scaled to the population prevalence for PTB [73]. Our estimate of s is
noticeably smaller than the maternal recurrence risk, scaled by population prevalence of
PPROM estimated in [73] (OR (95% CI): 20.6 (4.7, 90.2)). This difference likely reflects
the larger and population-based cohort used in our study, in contrast to [73] in which
relatively small groups of PPROM (n=114) and normal term (n=208) deliveries were
selected from a hospital population.
The utility of these measures lies primarily in establishing familial aggregation of
a disorder, a prerequisite to claiming genetic influences on any trait. Yet, s values may
also be used to make tentative assessments of future genetic studies. The magnitude of s
values may reflect the mode of genetic etiology, influencing future studies’ design. For
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example, for complex disorders, to which multiple genetic and environmental factors
likely contribute, reported s values range from 1.3-75, with peaks at 3-4 and 10-15 [88];
in contrast, monogenic Mendelian disorders show s values an order of magnitude higher
or more (e.g. cystic fibrosis s ~500 [87]). Thus, moderate values for s, such as those
reported for the adverse pregnancy outcomes studied (see Tables 2.1-2.4), are consistent
with complex genetic and environmental etiologies. Among complex disorders, s has
been used to estimate the ability of a study to detect specific genes [99]. However, large
values of s do not necessarily predict linkage [88; 100] or association [101] studies’
success. Additionally, measures that reflect the strength of a genetic effect detected either
by linkage, s calculated with respect to a specific locus, or by association, genotype
relative risk, γ, which measures the ratio of disease risks between individuals with and
those without the susceptibility genotypes, have only an indirect correlation with s
[101]. Moderate s values may correspond with high γ values (e.g. rheumatoid arthritis
[101]) and vice versa. While limitations in interpreting s values exist, disorders with
similar s values to the adverse pregnancy outcomes reported here have had specific
genes mapped (e.g. hypertension, obesity [88]), suggesting that identification of specific
genes influencing these conditions may be possible.
While the increased risk to siblings may be explained in part by shared genetics,
some evidence suggests that multiple interacting environment factors can account for
familial clustering [102]. Hence, the clustering of multiple non-genetic risk factors in
families may account for these results. In order to distinguish genetic from other familial
risk factors, we calculated sib-sib OR unadjusted and adjusted for important known
environmental risk factors. Overall, the elevated risk to siblings persists after adjustment
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for such factors. While there may be important non-genetic factors affecting each
outcome for which we have not accounted, we believe these results suggest that genetic
influences may contribute to each of the adverse pregnancy outcomes studied.
Interestingly, s and sib-sib OR estimates in Blacks are generally smaller than
those for Whites. For PROM and preeclampsia, the 95% CI for s and sib-sib OR
estimates for the two racial groups overlap; however, these CI do not overlap for PTB or
placental abruption. Hence, it is difficult to determine to what extent family clustering of
these outcomes may differ among races. Differences in the magnitude of s and sib-sib
OR estimates between Blacks and Whites may be explained in part by the higher
population prevalence for Blacks compared to Whites for each outcome studied (nonoverlapping 95% CI, see Tables 2.1-2.4), which may reflect higher overall rates of
genetic and/or environmental risk factors in this population.
The Missouri database provides many of this study’s strengths. The large number
of first recorded siblings in the population cohort (n=267,472) and matched sibpairs in
the sibling cohort (n=163,826) provides a large sample size from which to estimate s
and sib-sib OR. Additionally, because this database represents a population cohort of
births, rather than births selected based on any particular pregnancy outcome, biases due
to ascertainment and overreporting, which can inflate s values [103], should be minimal.
However, using a birth certificate database like this one also presents several
limitations. First, complications of labor and delivery and maternal and infant medical
conditions recorded in such databases may be underreported [104]; as a result, population
and/or sibling risk for a particular disorder may be underestimated, potentially biasing
our results. For example, the relative rarity of placental abruption in the population makes
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concordant sibships, particularly in Blacks, rare, thereby reducing sample sizes for risk
estimates for this disorder. Additionally, gestational age estimates contained in birth
certificate databases are based primarily on the date of the last menstrual period, which
may be recalled inaccurately or misclassified due to postconceptional bleeding [104],
potentially influencing estimates of PTB and PPROM prevalence in this dataset. We also
acknowledge that each of the categories of PTB that we analyzed may in themselves be
rather heterogeneous. For example, initiation of spontaneous labor may result in PTB in
each of the categories, though for some etiologies, particularly preeclampsia, iatrogenic
delivery could contribute significantly. Our utilization of a more rigorous definition of
PTB at less than 35 weeks should minimize the contribution of iatrogenic delivery. A
final important limitation to this database is the limited amount of information on race.
Maternal race is self-reported and possibly subject to population stratification and/or
admixture. Additionally, information on paternal race is incomplete, further affecting the
accuracy of infants’ reported race.
The Missouri database also does not document relationships between mothers; as
a result, similar calculations cannot be made to estimate familial clustering when the
mother of an affected pregnancy is considered the proband. Moreover, the database
contains little information on fathers, making it impossible to distinguish full from half
siblings in most sibships. Because we cannot distinguish siblings that share both maternal
and paternal factors from those that share maternal factors only, we cannot assess to what
extent the increased risk can be attributed to factors unique to the fetus, rather than those
shared with its mother. Due to these limitations, we cannot examine the relative
importance of maternal versus fetal genetic effects, studied by Wilcox et al. [29] and
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Cnattingius et al. [80], for PTB and preeclampsia, respectively. Cnattingius et al. [80]
reports 20% of variation in preeclampsia risk is due to fetal genetic effects and the
combined effect of fetal genetic factors and couple effects are as important as maternal
genetic effects. In contrast, Wilcox and colleagues [29] report only a weak association
between father’s family history and risk for PTB (RR (95% CI): 1.12 (1.01-1.25)), which
became nonsignificant at earlier gestational ages (RR (95% CI): 1.06 (0.77-1.44). From
this trend, the authors conclude that fetal genes may contribute to normal labor, but, not
preterm delivery [29]; however, Wilcox and colleagues [29] have relatively few early
preterm offspring of early preterm mothers (n=91) and fathers (n=39) from which risk
was estimated, and do not stratify based upon race/ethnicity. Similarly, a recent study
[21] suggested that paternal genetics contributed little to gestational age, but could not
refute the possible role of maternally-inherited genes expressed in the fetus. Hence, while
paternally-inherited genes may contribute little to PTB or other disorders, maternallyinherited genes expressed in the fetus may still be important. Because of our study’s
limitations, we may be detecting effects due to shared uterine environment, shaped in part
by maternal genes, rather than maternally-inherited genes in siblings. Hence, fetal genetic
effects may make contributions of lesser magnitude than maternal genetic factors, with
fetal genetic factors having a more prominent role in certain etiologies of PTB.
We have observed familial aggregation of PTB, PPROM, placental abruption and
preeclampsia. Overall, siblings are at increased risk for each outcome, even after
adjusting for important known environmental risk factors. While the influence of shared
unmeasured environmental risk factors on sibling risk cannot, and should not, be
discounted, we hypothesize that maternal and/or fetal genetic influences account for some
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of the increased risk to siblings observed. Moreover, though it is difficult to determine to
what extent fetal and maternal effects overlap in these analyses, we postulate that fetal
genetic factors may contribute to these disorders and suggest that they are studied further.
Methods
Study design. A protocol was approved by the Missouri Department of Health
and Senior Services and by Washington University School of Medicine to analyze the
state’s maternally linked birth-death certificate database. We analyzed this database to
assess the recurrence risk for a discrete group of adverse pregnancy outcomes, including
PTB, PPROM, placental abruption, and pre-eclampsia, in maternally-linked siblings.
Births to the same mother were linked by a unique identifier called a sibship number,
described elsewhere [105]. Full siblings and half-siblings resulting from pregnancies in
the same mother were not distinguished. All protected health information with personal
identifiers was removed before distributing the data for analysis.
This analysis was restricted to births that occurred between 1989 and 1997, since
births that occurred before 1989 lacked complete medical and social histories. Fetal
deaths occurring at <20 weeks gestation, multiple gestation pregnancies and individuals
with no maternally-linked siblings recorded in the database were excluded from this
analysis. After excluding such cases, the remaining cohort consisted of 473,881 births, of
which 383,812 (81.2%) were White and 81,889 (17.3%) were Black. 267,472 births
(220,728 (82.5%) White and 42,899 (16.0%) Black) were the first maternally-linked
sibling in the database and used to estimate the population prevalence for each outcome.
A second cohort of matched siblings was constructed from this dataset to analyze
sibling risk for each outcome. The two oldest siblings born to the same mother during the
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study period were included. The dataset was not restricted to parity 0 and parity 1
women, in order to be as unbiased as possible in estimating risk for siblings and
providing the best index of population prevalence. Additional siblings born to the same
mother were excluded to simplify the statistical model. This cohort comprised of 327,652
matched siblings, of which 265,947 (81.2%) were White and 55,555 (17.0%) were Black.
Second-born siblings whose older sibling was affected by a particular outcome were used
to estimate sibling risk for s and sib-sib OR.
Definitions. PTB is defined by the World Health Organization as delivery <37
weeks [1]. To avoid inclusion of borderline gestational ages which may introduce
misclassification bias, we defined PTB as delivery <35 weeks in this study. Information
from the last menstrual period and clinical data were used to calculate the best estimate of
gestational age. PPROM was defined as births delivered <35 weeks complicated by
premature rupture of membranes. For PPROM, births complicated by pre-eclampsia,
insulin-dependent and other diabetes, or eclampsia were excluded from analysis due to
the potential for these births being delivered for medical reasons. First-born sibling and
second-born sibling refer to the two oldest siblings recorded in database.
Statistical analysis

s

S

P(affected | affected sibling)
Population prevalence

was calculated as the frequency of an outcome in the individuals whose older

sibling was affected with the disorder in the sibling cohort divided by the frequency of
the outcome in first siblings in the larger cohort. 95% confidence intervals (CI) for
sibling risk, population risk and sibling risk ratio were calculated by standard procedures
for a binomial variable.
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Sib sib OR

P(affected | affected sibling)
P(affected | unaffected sibling)

Sib-sib OR was calculated as the odds of a child being affected with a particular
adverse outcome, given that their older sibling was affected, divided by the odds of a
child being affected with a particular adverse outcome, given that their older sibling was
unaffected. Sib-sib OR were adjusted for known medical and environmental risk factors
for the outcome to most conservatively estimate residual familial effects on risk. For
preterm-birth and PPROM, OR were adjusted for: mother’s age <20 years old, mother
<12 years of education, recipient of state-funded assistance (an index of low
socioeconomic status), no prenatal care, mother’s body mass index (BMI) <20 kg/m2, and
cigarette smoking during pregnancy. In addition to these risk factors, preeclampsia ORs
were corrected for: mother’s age >35years old, insulin-dependent diabetes mellitus,
chronic hypertension. ORs for placental abruption were corrected for
hydraminos/oligohydraminos in addition to the risk factors listed above.
Frequencies for

S

and logistic regression analyses for the sib-sib OR were

performed using Stata 9 [106]. Each calculation was made for PTB, PPROM, placental
abruption, and preeclampsia in all races (including individuals whose race was neither
Black nor White), as well as stratified by Black or White race.

S

and sib-sib ORs

calculated by race compare siblings of affected individuals designated as Black or White
to the siblings of unaffected individuals of the same race or the population prevalence for
that race.
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0.123
(0.113-0.133)

0.156
(0.147-0.165)
4.3 (4.0-4.6)
5.6 (5.2-6.0)
4.2 (3.9-4.5)

Sibling Risk

s (95% CI)
Sib-sib unadjusted OR (95% CI)
Sib-sib adjusted OR (95% CI)#

2.8 (2.6-3.1)
3.6 (3.2-4.0)
3.3 (2.9-3.7)

0.221
(0.204-0.238)

2210

489

0.078
(0.075-0.081)

Black
3354
42899

#Adjusted for mother <20 years old, mother <12 education, Medicaid (index of low SES), no prenatal care, mother BMI <20 kg/m2,
cigarette smoking

4.4 (4.0-4.7)
5.7 (5.2-6.3)
5.1 (4.6-5.7)

4181

6522

Siblings: sibpairs with first sibling delivered preterm

514

1020

0.028
(0.027-0.029)

0.036
(0.035-0.037)

Siblings: sibpairs with both siblings delivered preterm

Population Risk

Population: Preterm births
Population: Total births

White
6232
220728

All Races
9759
268103

Table 2.1: Estimated sibling risk ratio (s) and sibling-sibling odds ratio (sib-sib OR) for PTB <35 weeks.
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0.006
(0.006-0.006)
37
883
0.042
(0.029-0.055)
6.8 (4.6-8.9)
8.8 (6.3-12.4)
8.5 (6.0-12.1)

0.008
(0.008-0.008)
88
1300
0.068
(0.054-0.082)
8.2 (6.5-9.9)
10.8 (8.6-13.5)
9.6 (7.6-12.2)

0.125
(0.092-0.158)
6.4 (4.7-8.1)
8.8 (6.4-12.1)
8.9 (6.4-12.5)

393
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0.019
(0.018-0.020)

39190

763

Black

#Adjusted for mother <20 years old, mother <12 education, Medicaid (index of low SES), no prenatal care, mother BMI <20 kg/m2,
cigarette smoking

Sibling risk
s
Sib-sib unadjusted OR (95% CI)
Sib-sib adjusted OR (95% CI)#

Population risk
Siblings: sibpairs with both siblings delivered
after PPROM
Siblings: sibpairs with first sibling delivered
after PPROM

211308

254740

Population: N

1311

2105

White

Population: PPROM

All Races

Table 2.2: s and sib-sib OR (with 95% CI ) for PPROM.
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30
851
0.035
(0.023-0.047)
4.9 (3.2-6.7)
5.4 (3.8-7.9)
5.0 (3.4-7.4)

34
1124
0.030
(0.020-0.040)
4.0 (2.6-5.3)
4.1 (2.9-5.8)
3.8 (2.6-5.5)

245
0.016
(0-0.032)
1.6 (0.0-3.2)
1.4 (0.5-3.7)
1.2 (0.4-3.9)

4

Black
428
42888
0.010
(0.009-0.011)

#Adjusted for mother <20 or >35years old, mother <12 education, Medicaid (index of low SES), no prenatal care, mother BMI <20
kg/m2, cigarette smoking, insulin-dependent diabetes mellitus, chronic hypertension, hydraminos/oligohydraminos

Sibling risk
s
Sib-sib unadjusted OR (95% CI)
Sib-sib adjusted OR (95% CI)#

Population risk
Siblings: sibpairs with both siblings from pregnancy
affected with placental abruption
Siblings: sibpairs with first sibling delivered from
pregnancy affected with placental abruption

Population: placental abruption
Population: N

White
1579
220641
0.007
(0.007-0.007)

All races
2050
268002
0.008
(0.008-0.008)

Table 2.3: s and sib-sib OR (with 95% CI) for placental abruption.

36
8.1 (7.5-8.8)

Sib-sib adjusted OR (95% CI)#

9.0 (8.2-9.8)

10.0 (9.1-10.9)

5.8 (4.9-7.0)

6.7 (5.7-7.9)

4.1 (3.6-4.6)

1400
0.166
(0.146-0.186)

233

Black
1736
42861
0.041
(0.039-0.043)

#Adjusted for mother <20 or >35years old, mother <12 education, Medicaid (index of low SES), no prenatal care, mother BMI <20
kg/m2, cigarette smoking, insulin-dependent diabetes mellitus, chronic hypertension

9.2 (8.5-9.9)

Sib-sib unadjusted OR (95% CI)

4.5 (4.2-4.8)

5869
0.140
(0.131-0.149)

7384
0.145
(0.137-0.153)
4.5 (4.2-4.8)

821

1070

s

Sibling risk

Population risk
Siblings: sibpairs with both siblings from pregnancy
affected with preeclampsia
Siblings: sibpairs with first sibling from pregnancy
affected with preeclampsia

Population: preeclampsia
Population: N

White
6749
220505
0.031
(0.031-0.031)

All races
8600
267840
0.032
(0.031-0.033)

Table 2.4: s and sib-sib OR (with 95% CI) for preeclampsia.

Chapter 3: Patterns of inheritance suggest familial PTB is complex genetic disorder‡

Abstract
While multiple lines of evidence suggest the importance of genetic contributors to
risk of PTB, the nature of the genetic component has not been identified. We perform
segregation analyses to identify the best fitting genetic model for gestational age, a
quantitative proxy for PTB. Because either mother or infant can be considered the
proband from a preterm delivery and there is evidence to suggest that genetic factors in
either one or both may influence the trait, we performed segregation analysis for
gestational age either attributed to the infant (infant’s gestational age), or the mother (by
averaging the gestational ages at which her children were delivered), using 96 multiplex
preterm families.
These data lend further support to a genetic component contributing to birth
timing since sporadic (i.e. no familial resemblance) and nontransmission (i.e.
environmental factors alone contribute to gestational age) models are strongly rejected.
Analyses of gestational age attributed to the infant support a model in which mother’s
genome and/or maternally-inherited genes acting in the fetus are largely responsible for
birth timing, with a smaller contribution from the paternally-inherited alleles in the fetal
genome. Our findings suggest that genetic influences on birth timing are important and
likely complex.

‡

This chapter is adapted from: Plunkett J, et al. (2009) Mother’s genome or maternally-inherited
genes acting in the fetus influence gestational age in familial PTB. Hum Hered 68:209-219.
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Introduction
While multiple lines of evidence suggest genetic contributors are important in
PTB, a specific mode of inheritance has not been identified. No prominent simple
Mendelian pattern of inheritance has been observed in multiplex pedigrees identified to
date. Modeling procedures used by twin studies suggest that additive genetic factors and
environmental risk factors that are not shared among siblings both influence PTB [1921]. Moderate values of sibling risk ratio ( S), a measure of risk to siblings of affected
individuals compared to the population risk for a disorder, estimated for PTB (

S

(95%

CI): 4.3 (4.0-4.6)) [107] are also consistent with complex genetic and environmental
etiologies [88]. Moreover, association studies have reported gene-gene [33; 34] and geneenvironment [35; 108; 109] interactions with PTB. Together, these studies imply that the
etiology of PTB likely involves genetic as well as environmental factors in complex
interactions. However, there has not been a systematic study of possible genetic models
for PTB to date.
In this study, we performed segregation analyses to identify the best fitting
genetic model for gestational age, a quantitative proxy for PTB. Because either mother or
infant can be considered the proband from a preterm delivery, and there is evidence to
suggest that genetic factors in either one or both may influence the trait, we performed
segregation analysis for gestational age as a quantitative trait either attributed to the
infant, infant’s gestational age, or to the mother, by averaging the gestational ages at
which her children were delivered, using 96 multiplex preterm families. We also tested
parent of origin models for infant’s gestational age to examine whether mother’s
genotype is the sole determinant of variation in this trait. Additionally, as pregnancies in
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which either the mother [10; 13] or father [6; 7] is Black are at increased risk for preterm
delivery, we performed segregation analysis for each phenotype in the total sample, as
well as stratified by Black and White race, to test for heterogeneity between these two
groups.
Results
Modeling of gestational age attributed to the infant. We first analyzed
gestational age of the infant. The number of subjects and descriptive statistics for this
phenotype are shown in Table 3.1. Table 3.2 presents the likelihood ratio tests (LRTs)
and Akaike’s Information Criterion (AIC) values for segregation analysis of infant’s
gestational age for 17 models of inheritance. The parameter estimates for segregation
analysis of infant’s gestational age are listed in Table 3.1. The hypotheses of no familial
resemblance (model 2), no major gene effect (model 3), and no multifactorial effect
(model 4) are rejected, suggesting the presence of both a major gene and a multifactorial
effect. Additionally, the equal τ's hypotheses (models 10, 12 and 14) are rejected for the
mixed, recessive mixed and dominant mixed models, respectively. In the free τ's models,
the estimated τAa differed from 0.5, expected under the Mendelian model, and fit the data
better than their respective general models (models 1, 7 and 8) for all groups. Together,
this evidence supports a genetic component for PTB transmitted from parents to offspring
and suggests that the transmitted effect is complex. Similar models were tested for
general parent of origin effects, as well as maternal-specific and paternal-specific effects
under Mendelian transmission (models 15-17). The parent of origin model (model 15)
best fit the data as judged by AIC values and was chosen as the most parsimonious model
(Table 3.3). This model suggests that, when attributing gestational age to the infant of a
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delivery, genetic factors influence this trait and the parent from whom such factors are
inherited influences the overall trait value.
Modeling of gestational age attributed to the mother. We also analyzed
gestational age attributed to the mother, by averaging the gestational ages at which her
children were delivered (see Table 3.1). Table 3.2 presents the likelihood ratio tests and
AIC values for segregation analysis on mother’s average gestational age of children for
14 models of inheritance. The parameter estimates for the combined dataset are listed in
Table 3.4. The hypotheses of no familial resemblance (model 2), no major gene effect
(model 3), and no multifactorial effect (model 4) are rejected, suggesting the presence of
both a major gene and a multifactorial effect. The equal τ's (models 10, 12 and 14) are
rejected. None of the free τ's models (models 9, 11 and 13) converged initially. In order to
estimate these models, τAA and τaa were fixed to 1 and 0, respectively. Only τAa was
estimated and, in each case, differed from 0.5, expected under the Mendelian model.
Additionally, the free τ's models fit the data better than their respective general models
(models 1, 7 and 8), perhaps suggesting that the major effect observed is more complex
than the single biallelic locus modeled here. Together, this evidence supports a genetic
component for PTB transmitted from parents to offspring and suggests that the
transmitted effect is complex. The mixed free ’s model (model 9) best fit the data as
judged by the AIC values and was chosen as the most parsimonious model (Table 3.5).
This model suggests that a multifactorial genetic model most likely best accounts for
variation in gestational age, when the trait is attributed to the mother of a delivery.
Heterogeneity between Blacks and Whites. Since pregnancies in which either
the mother [10; 13] or father [6; 7] is Black are at increased risk for preterm delivery, we
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tested for evidence of genetic heterogeneity between these two groups. Segregation
analyses of infant’s gestational age and mother’s average gestational age over all her
children also were performed in Black and White subgroups. Table 3.1 documents the
number of subjects and descriptive statistics for both phenotypes by race. The segregation
analyses of infant’s gestational age supported similar conclusions in the combined sample
and Black and White subgroups. However, several results differed in the segregation
analysis of mother’s average gestational age of children when the sample was stratified
by Black and White race, compared to the combined sample. In the race-stratified
samples, final estimates of the free τ's models had higher -2ln likelihoods than did similar
models with fewer parameters, indicating that the maximum likelihood was not reached.
As a result, the equal τ's hypotheses (models 10, 12 and 14) and the free τ's hypotheses
(models 9, 11 and 13) were not rejected for the mixed, recessive mixed and dominant
mixed models, respectively, in Black and White subgroup analysis. The best fitting
model according to AIC values was the mixed equal τ's model and was selected as the
most parsimonious model in both race subgroups (data not shown).
To test formally for heterogeneity between Blacks and Whites, we used the
heterogeneity

2

test [110; 111] in which the -2lnL value under a given model for the

combined data is subtracted from the summed -2lnL values from stratified analyses. For
infant’s gestational age, evidence for genetic heterogeneity among races was observed
when comparing values under the multifactorial model (

2

=

698.07 Black + 2010.02

White) -2690.72 combined =17.37, 3 df, p=0.0006). Of note, parameter estimates for
Blacks and Whites differed, particularly estimates of p, H and

AA which

were generally

higher in Blacks than Whites. For the multifactorial model, H was estimated as 0.46
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(95% CI: 0.27, 0.65) for Blacks and 0.23 (95% CI: 0.13, 0.33) for Whites. While these
point estimates are quite different, the 95% CI overlap, indicating that this difference may
not be statistically significant. For mother’s average gestational age of children, evidence
for genetic heterogeneity among races was observed when comparing values under the
multifactorial model (

2

=

(54.92 Black +213.58 White)-216.37 combined =52.13, 3 df,

p=2.81x10-11). Of note, parameter estimates for Blacks and Whites differed, particularly
estimates of H, which are generally higher in Blacks than Whites. For the mixed free τ's
model, H was estimated as 0.70 (95% CI: 0-1) for Blacks and 0.23 (95% CI: 0-0.57) for
Whites. As the 95% confidence intervals overlap, this difference is not significant in the
sample size analyzed here.
Discussion
PTB likely has a complex etiology involving both genetic and environmental risk
factors, based on evidence from previous studies. This study is the first to explicitly test
different modes of inheritance for birth timing, by assessing gestational age as a
phenotype of either mother or infant. These data lend further support to a genetic
component contributing to birth timing since sporadic (i.e. no familial resemblance) and
nontransmission models, in which gestational age is attributed to environmental factors
alone, are strongly rejected (Tables 3.2 and 3.4). Our findings suggest that genetic
influences on birth timing are important and likely complex.
For infant’s gestational age, the parent of origin model (model 15) best fit the data
according to the AIC values and was chosen as the most parsimonious model (Table 3.2).
Based on the mean estimates for AA, Aa, aA and aa under this model (Table 3.3), it
appears that this parent of origin effect is largely maternal. Heterozygotes who inherit the
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A allele from their mother (Aa) have a mean closer to, but not equal to, AA. Under a
strict maternal model, AA and Aa would be equivalent, since mother’s A allele would be
expected to be the sole determinant of phenotype. In contrast, heterozygotes who
inherited the A allele from their father (aA) have a mean that is approximately equivalent
to that of aa, suggesting that father’s A allele has little effect on phenotype. A model in
which the maternally-inherited allele was the sole determinant of the phenotype (model
16) did not fit the data better than the parent of origin model in which the entire genotype
was considered. Importantly, father’s genes also affect phenotype in this model, aligning
with previous work showing paternity [26; 27] as well as paternal race [6; 7] influence
PTB risk. Hence, both maternal and paternal alleles seem to contribute to infant’s
gestational age, with maternally-inherited alleles having a stronger effect on phenotype
than those inherited from the father. This finding may support previous studies that have
observed stronger effects of mother’s race [6; 7] and family history on risk for PTB [29]
than those of the father.
These data suggest that maternally-inherited genes acting in the fetus and/or
maternal genes acting in the mother are largely responsible for birth timing; however,
these two possibilities are not easily distinguished. Maternal genetic effects can create the
same pattern of phenotypic variation as genomic imprinting [112]. These two classes of
effects can be distinguished by comparing the offspring of heterozygous mothers [112];
however, such comparisons are not possible in our dataset in which individuals were
assigned probabilities for each possible genotypic state, rather than having known
genotypes measured empirically. Previous studies in cattle [113; 114] have observed
maternal genetic effects on gestational age, but did not consider parent of origin effects.
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Consequently, further study is needed to determine whether maternal effects or
imprinting account for our observations. In either case, considering the mother of a
preterm delivery as proband may be most useful in identifying genetic contributions to
PTB.
Segregation analysis of mother’s average gestational age of children also
supported a complex genetic model. The mixed free τ's model (model 9) best fit the data
according to the AIC values and was chosen as the most parsimonious model (Table 3.4).
This model, in combination with results from LRTs, suggests that genetic influences on
birth timing are important and likely complex. Importantly, fewer individuals are
informative when mother is considered the proband in a preterm delivery (Figure 3.1),
and the smaller sample size affects the power of the analysis. As a result, the parameter
and likelihood estimates made when considering mother as proband are more affected by
sampling variance; however, conclusions made by comparing across models should be
less affected by sample size.
Overall, mother-based and infant-based analyses both support the importance of
genetic factors, perhaps primarily acting in the mother or maternally-inherited alleles
acting in the fetus, in birth timing. The genetic component influencing PTB likely
involves many genes in interaction with environmental and other genetic factors. These
results are consistent with previous studies suggesting that genes and environments [1921], as well as gene-gene [33; 34] and gene-environment [35; 108; 109] interactions
influence PTB. Estimates from the multifactorial model (model 3, Tables 3.3 and 3.5)
indicate 30-40% of variation in gestational age, attributed to either mother or infant, can
be explained by genetics, consistent with estimates from previous twin studies [19; 21].
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As twins may not be representative of the population as a whole, our heritability
estimates corroborate the general importance of genetics in birth timing. Heritability
estimates were generally higher in mother-based analyses (0.44 (95% CI: 0.11, 0.77))
than in infant-based analysis (0.33 (95% CI: 0.24, 0.42)), but not significantly different
(Tables 3.3, 3.5). While many genes may be contributing to the observed genetic
influence on birth timing, the moderate heritability observed suggests that the cumulative
effect of these genes accounts for an important amount of variation in gestational age.
Although alternative methods for segregation analysis exist, we considered the
Pedigree Analysis Package (PAP) to be the best method for our primary goal of
identifying the best-fitting genetic model for birth timing. Using PAP, we were able
compare models directly and identify the most parsimonious model. In contrast, Markov
Chain Monte Carlo (MCMC) methods, such as those used by the Loki [115] and Morgan
[116] packages, generate a series of posterior probabilities for various models, but no one
model is identified as superior. Moreover, MCMC methods model several Mendelian loci
simultaneously but do not include a polygenic component, which we wanted to include in
the models we examined. Furthermore, one cannot correct for ascertainment within
MCMC analysis, in contrast to PAP. One of the disadvantages of using PAP exclusively
was that we were not able to estimate the approximate number of loci contributing to
birth timing, as could be done with MCMC methods. Additionally, MCMC methods may
be better at handling large, complex pedigrees than PAP [117]; however, since our
families were relatively small and simple (e.g. containing no inbreeding), we did not
consider this a limitation.
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We have likely enriched for genetic and/or common environmental effects by
using 96 multiplex families, all of whom were recruited based on having two or more
first degree relatives delivered preterm. These multiplex families provided a large sample
size from which genetic effects could be examined. However, the ascertainment scheme
also introduces bias, as the families were not collected randomly and may overestimate
the importance of certain genetic models. To minimize errors due to such bias, all
analyses were corrected for ascertainment by conditioning on the initial proband, either
the mother or the offspring depending which phenotype was considered, that led to the
ascertainment of the family, assuming single ascertainment. However, if our assumption
of single ascertainment is incorrect, conditioning on probands in this manner may create
bias in estimating model parameters [118], leading to inaccurate conclusions about the
best-fitting model for familial PTB. Because we believe our ascertainment scheme is
consistent with single ascertainment, these results appear to be most appropriate for
modeling genetic effects in familial PTB. Yet, it is possible that our conclusions drawn
from familial cases of PTB may not generalize to all instances of this disorder. Familial
cases of PTB may have a different genetic contribution than isolated cases, perhaps
having different etiologies than isolated cases.
This study is also limited by the phenotypes studied. Information on gestational
age was collected by self-report data from questionnaires for many individuals used in
this analysis. While it was possible to verify gestational ages from medical records in
some cases, including all births delivered at the participating institutions, many
gestational ages could not be verified and may be subject to reporting errors.
Additionally, many individuals for whom we could not verify precise gestational ages
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were reported as “full term” and assigned gestational age of 40 weeks. While this is the
most likely gestational age for infants to be born [12], we may lose some variability in
the overall distribution of gestational age by doing so. As modeling of trait variance is
essential to segregation analysis, this approach also may have affected our results.
Our findings suggest that genetic influences on birth timing are important.
Modeling for both mother and infant phenotypes indicate that a genetic component
influences gestational age and is complex in nature. In analyses using either mother or
infant as proband, monogenic Mendelian models were strongly rejected, suggesting that a
single gene model cannot fully explain birth timing in these families. A number of genes
probably contribute to the genetic influence on birth timing and PTB described. Analyses
of gestational age attributed to the infant support a model in which mother’s genome
and/or maternally-inherited genes acting in the fetus are largely responsible for birth
timing, with a smaller contribution from the paternally-inherited alleles in the fetal
genome. Hence, considering the mother of a preterm delivery as proband may be more
useful in identifying specific genetic contributions to PTB. Interestingly, results from the
heterogeneity

2

test comparing race-stratified analyses suggest that genetic influences on

birth timing may differ between Blacks and Whites. Hence, in future association studies,
race-stratified analyses or population stratification corrections may improve our ability to
identify specific genes associated with PTB. Overall, as multiple genes in the mother’s
genome may explain the bulk of genetic influences on birth timing, future studies to
identify specific genes influencing PTB perhaps will be most fruitful by using large scale
studies of mothers’ genomes.
Material and Methods
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Proband mother-infant pair was initially identified through premature birth of a
live singleton fetus before 37 weeks of gestation [1] by review of delivery logs at
university medical center hospitals at Washington University and University of Helsinki
or by self-identification through the study’s website from 2003 to October 2007. To avoid
misclassification bias at borderline gestational ages, we defined PTB as <35 weeks in the
US cohort and <36 weeks in the Finland cohort. Our gestational age criteria was less
stringent in the Finland cohort due to the high number of early ultrasounds performed,
leading to more accurate gestational ages in this cohort. To include only families with
spontaneous onset of preterm singleton birth, the following mother-infant pairs were
further excluded: elective deliveries without spontaneous onset of labor and deliveries in
which either maternal (e.g. systemic infection) or fetal (e.g. malformation) disease with
known predisposition to premature birth was indicated. Families were extended through
affected individuals on both maternal and paternal sides until no additional first degree
relatives were identified as either mother of infant of a preterm delivery. Families were
recruited into the study only if two or more members were mothers and/or infants of
preterm deliveries. 55 families were recruited from the US, of which 31 were Black and
24 were White. 41 White families were recruited from Finland. In the US cohort, families
ranged from 9 to 36 individuals with phenotypic information with a median family size of
18 individuals. In the Finland cohort, families ranged from 8 to 73 individuals with
phenotypic information with a median family size of 16 individuals. Informed consent
was obtained from participants and the study was approved by the institutional review
board of Washington University School of Medicine and the ethics committee of Helsinki
University Central Hospital.
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From the US cohort, an individual’s gestational age was calculated based on his
or her mother’s self report of expected due dates and actual delivery dates for a
pregnancy or of how many weeks early that family member was born. For all individuals
born at the Washington University School of Medicine, gestational ages were verified
from medical records. From the Finland cohort, an individual’s gestational age was
obtained from medical records. Individuals for whom pedigree information indicated that
they were born <35 or <36 weeks without a specific gestational age designated were
assigned a gestational age of 34 or 35 weeks, respectively. Similarly, those individuals
indicated as “term” were designated 40 weeks. Infant’s gestational age was treated as a
quantitative trait, which was standardized to a normal distribution ( =0, =1) prior to any
analysis. A total of 1378 individuals had non-missing phenotypes, with a median of 13
individuals per family (range 3-80). The number of sibpairs with phenotypic information
for this phenotype was 309, with a median of 3 sibpairs per family (range 1-7). The
median number of generations with phenotypic information was 3 (range 1-5).
For both cohorts, a variable representing the average gestational age of all
children born to a given mother was constructed. For mothers who had one or more
children born before 37 weeks, this variable was calculated as the mean of the gestational
ages for all children born to that woman. Mothers who gave birth to all of their children
at term (>37 weeks) were assigned a value of 40 weeks. Mothers for whom one or more
children had missing gestational ages were coded as missing. Additionally, all males and
females who had not yet given birth were coded as missing. This phenotype was treated
as a quantitative trait, which was standardized to a normal distribution ( =0, =1) prior
to any analysis. Univariate statistics and standardizations for each phenotype were
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performed with SAS language v. 9.1.3 for Linux OS (SAS Institute, Cary, NC). A total of
404 individuals had non-missing phenotypes, with a median of 4 individuals per family
(range 1-17). The number of sibpairs with phenotypic information for this phenotype was
309, with a median of 0 sibpairs per family (range 0-5). The median number of
generations with phenotypic information was 2 (range 1-4).
We used the Pedigree Analysis Package (PAP), Version 5.0 [119] to perform
segregation analysis. Under the mixed Mendelian model (model 1), the phenotype is
influenced by a major gene, polygenic background and an untransmitted environmental
component. The major gene is biallelic (A, a), with allele A, occurring at frequency p,
associated with lower trait values. Mean values for the three genotypes (μAA, μAa, μaa,
where the order of the means is constrained to be μAA ≤ μAa ≤ μaa) and a common
standard deviation for all genotypes are estimated. Parent-to-offspring transmission
probabilities for the three genotypes (τAA, τAa, and τaa) also are included in the model. τAA,
τAa, and τaa designate the probability of transmitting allele A for the genotypes AA, Aa,
and aa, with Mendelian expectations of 1, 0.5, 0, respectively. When the τ’s are set equal
to p, there is no transmission of the major effect. Polygenic heritability (H) after
accounting for the putative major gene effect was also estimated. For parent of origin
models, heterozygotes who inherited A from their mother (Aa) and heterozygotes who
inherited A from their father (aA) are distinguished from one another and allowed to have
different means. Many of the free τ's models did not converge initially. In order to
estimate these models, τAA and τaa were fixed to 1 and 0, respectively, and likelihoods
calculated under these additional assumptions were used for the analysis.
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All parameters were estimated using a maximum likelihood method. Nested
models representing null hypotheses were tested against a more general model using a
LRT, in which the difference between negative twice the log-likelihood (-2 ln L) values
for two models approximates a chi-square distribution with degrees of freedom equal to
the number of independent parameter restrictions. The most parsimonious model of those
not rejected by likelihood ratio test (p>0.01) was determined using AIC [120], which is
computed as -2 ln L of the model plus twice the number of parameters estimated. The
model with the lowest AIC indicates the most parsimonious fit to the observed data.
To account for the ascertainment of the families, the likelihood of each model was
conditioned on the likelihood of the proband’s phenotype under the model, an appropriate
correction for the manner in which these families were extended [121]. While our
criterion required 2 or more preterm first degree relatives for a family to be enrolled in
the study, the ascertainment scheme is approximately equivalent to single ascertainment
[122]. Because not all preterm deliveries in the metropolitan St. Louis or Finnish health
care systems occurring during the study period were captured under our ascertainment
scheme, the probability that a family was identified through multiple probands is small
and should be proportional to the number of affected deliveries in a family, as expected
under single ascertainment[123]. Under single ascertainment, conditioning on the
proband’s phenotype is sufficient to adjust for the ascertainment of families [123]. Hence,
analyses for infant’s gestational age were corrected for the proband infant’s gestational
age jointly with PTB (<37 weeks) affection status. Similarly, analyses attributing
gestational age to the mother were corrected for the proband mother’s average gestational
age of children jointly with her PTB (<37 weeks) affection status.
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To test genetic heterogeneity among races, we used the heterogeneity

2

test [110;

111] in which the -2lnL value under the best fitting model for the combined data is
subtracted from the summation of -2lnL values for stratified analyses to obtain the test
statistic. This test statistic approximates a

2

distribution with df equal to K*J-K where J

is the number of subgroups and K is the number of parameters in the model.
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Question marks indicate that the gestational age for that individual is unknown. Panel A depicts the pattern of affection status (<37
weeks) if the infant is considered proband of a preterm delivery. Multiple births are excluded due to the likelihood of singleton and
multiple births having different mechanisms for early birth.

Preterm birth, infant as affected

Figure 3.1A: A representative pedigree of familial preterm birth with gestational age in weeks of each individual indicated.
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Question marks indicate that the gestational age for that individual is unknown. Panel B depicts the pattern of affection status (<37
weeks) if the mother is considered proband of a preterm delivery. Multiple births are excluded due to the likelihood of singleton and
multiple births having different mechanisms for early birth.

Preterm birth, mother as affected

Figure 3.1B: A representative pedigree of familial preterm birth with gestational age in weeks of each individual indicated.
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Infant’s gestational age
N (% <37 weeks)
Mean
Standard deviation
Kurtosis
Skewness
Mother’s average gestational age
N (% <37 weeks)
Mean
Standard deviation
Kurtosis
Skewness
301 (41.53%)
36.12
4.83
0.24
-1.08
48 (70.83%)
34.22
4.45
-0.66
-0.32

191 (54.97%)
35.69
4.24
-0.24
-0.76

Blacks

1130 (33.63%)
37.12
4.09
1.73
-1.45

Combined

143 (49.65%)
36.19
4.07
0.17
-0.95

829 (30.76%)
37.49
3.73
2.47
-1.58

Whites

Table 3.1: General characteristics of the study subjects as a single cohort and stratified by race.
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Mixed
Sporadic
Multifactorial
Additive
Recessive
Dominant
Mixed recessive
Mixed dominant
Mixed free ’s
Mixed equal ’s
Recessive free ’s
Recessive equal ’s
Dominant free ’s
Dominant equal ’s
Parent of origin #
Maternal
Paternal

# most parsimonious model

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

Model

Estimated
parameters
6
2
3
5
4
4
5
5
9
6
8
5
8
5
6
4
4
2266.85
2754.87
2690.72
2303.33
2545.26
2305.64
2544.08
2270.77
2100.61
2354.73
2291.99
2354.73
2106.20
2354.73
2078.97
2320.79
2356.23

"-2lnL"
488.02
423.87
36.48
278.41
38.79
277.23
3.92
166.24
254.12
252.09
62.74
164.57
248.53
260.83
296.27

16 vs 15
17 vs 15

2

2 vs 1
3 vs 1
4 vs 1
5 vs 1
6 vs 1
7 vs 1
8 vs 1
1 vs 9
10 vs 9
7 vs 11
12 vs 11
8 vs 13
14 vs 13

test

3
3

4
3
1
2
2
1
1
3
3
3
3
3
3

df

p < 0.001
p < 0.001

p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
0.05
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001

p-value

2278.85
2758.87
2696.72
2313.33
2553.26
2313.64
2554.08
2280.77
2118.61
2366.73
2307.99
2364.73
2122.20
2364.73
2090.97
2328.79
2364.23

AIC

Table 3.2: Segregation analysis of infant’s gestational age in 96 multiplex families (n=1224 nonfounders).
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P
0.27
[1]
[1]
0.27
0.03
0.26
0.03
0.27
0.05
0.33
0.01
0.06
0.05
0.33
0.20
0.09
0.12
[1]
[1]
[1]
[1]
[1]
[1]
[1]
[1]
1.00
[p]
0.98
[p]
1.00
[p]
[1]
[1]
[1]

AA

[0.5]
[0.5]
[0.5]
[0.5]
[0.5]
[0.5]
[0.5]
[0.5]
0.99
[p]
0.70
[p]
0.98
[p]
[0.5]
[0.5]
[0.5]

Aa

[0.5]
[0.5]
[0.5]
[0.5]
[0.5]
[0.5]
[0.5]
[0.5]
[ Aa]
[p]
[ Aa]
[p]
[ Aa]
[p]
[0.5]
[0.5]
[0.5]

aA

aa

[0]
[0]
[0]
[0]
[0]
[0]
[0]
[0]
0.16
[p]
0.04
[p]
0.16
[p]
[0]
[0]
[0]

Transmission probabilities

-1.73
0.01
0.24
-1.82
-1.55
-1.84
-1.56
-1.75
-1.60
-1.84
-1.77
-1.84
-1.56
-1.84
-2.38
-1.71
-1.81

AA
a

0.52
[ AA]
[ AA]
0.46a
[ AA]
0.39
[ AA]
0.45
0.42
0.40
[ AA]
[ AA]
0.49
0.40
-0.69
[ AA]
0.39

Aa

[ Aa]
[ AA]
[ AA]
[ Aa]
[ Aa]
[ Aa]
[ Aa]
[ Aa]
[ Aa]
[ Aa]
[ Aa]
[ Aa]
[ Aa]
[ Aa]
0.60
0.40
[ AA]

aA

aa
a

0.37
[ AA]
[ AA]
0.31a
0.32
[ Aa]
0.33
[ Aa]
0.58
0.40
0.42
0.40
[ Aa]
[ Aa]
0.58
[ Aa]
[ Aa]

Mean values for genotypes

# Most parsimonious model. [ ] denotes that the parameter was set and not estimated.
a
Parameter estimates are approximately equal within standard error.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

Model
Mixed
Sporadic
Multi-factorial
Additive
Recessive
Dominant
Mixed-recessive
Mixed-dominant
Mixed- free ’s
Mixed-equal ’s
Recessive free ’s
Recessive equal ’s
Dominant free ’s
Dominant equal ’s
Parent of origin #
Maternal
Paternal

A allele
frequency

0.56
0.92
0.91
0.56
0.71
0.57
0.71
0.56
0.55
0.58
0.57
0.58
0.55
0.58
0.37
0.57
0.57

Common
standard
deviation

H
0.38
[0]
0.33
[0]
[0]
[0]
0.05
0.36
0.42
0.28
0.25
0.28
0.40
0.28
[0]
[0]
[0]

Heritability

Table 3.3: Parameter estimates for segregation analysis of infant’s gestational age in 96 multiplex families (n=1224
nonfounders).
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Model
Mixed
Sporadic
Multifactorial
Additive
Recessive
Dominant
Mixed recessive
Mixed dominant
Mixed free ’s * #
Mixed equal ’s
Recessive free ’s *
Recessive equal ’s
Dominant free ’s *
Dominant equal ’s

"-2lnL"
175.06
222.42
216.37
181.57
187.88
182.62
186.70
175.68
153.94
173.56
184.09
173.56
157.15
173.56
2 vs 1
3 vs 1
4 vs 1
5 vs 1
6 vs 1
7 vs 1
8 vs 1
1 vs 9
10 vs 9
7 vs 11
12 vs 11
8 vs 13
14 vs 13

test
47.36
41.31
6.50
12.82
7.55
11.63
0.62
21.13
19.62
2.60
-10.54
18.53
16.40

2
4
3
1
2
2
1
1
3
3
3
3
3
3

df
p < 0.001
p < 0.001
0.01
0.002
0.02
p < 0.001
0.43
p < 0.001
p < 0.001
0.46
N/A
p < 0.001
p < 0.001

p-value

AIC
187.06
226.42
222.37
191.57
195.88
190.62
196.70
185.68
167.94
185.56
196.09
183.56
169.15
183.56

# most parsimonious model
* indicates the model did not converge on its own. AA was set equal to 1 and aa set equal to 0 in order to estimate the model.

1
2
3
4
5
6
7
8
9
10
11
12
13
14

Estimated
parameters
6
2
3
5
4
4
5
5
7
6
6
5
6
5

Table 3.4: Segregation analysis of mother’s average gestational age of children in 96 multiplex families (n=192 nonfounders).
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p
0.27
[1]
[1]
0.25
0.04
0.28
0.04
0.28
0.16
0.40
0.02
0.08
0.18
0.40
[1]
[1]
[1]
[1]
[1]
[1]
[1]
[1]
[1]
[p]
[1]
[p]
[1]
[p]

AA

[0.5]
[0.5]
[0.5]
[0.5]
[0.5]
[0.5]
[0.5]
[0.5]
0.77
[p]
0.66
[p]
0.75
[p]

Aa

Transmission
probabilities

[0]
[0]
[0]
[0]
[0]
[0]
[0]
[0]
[0]
[p]
[0]
[p]
[0]
[p]

aa

-1.02
0.55
0.74
-1.28
-0.94
-1.08
-1.06
-1.01
-1.01
-1.00
-0.85
-1.00
-0.96
-1.00

AA

0.89
[ AA]
[ AA]
0.72
[ AA]
0.87
[ AA]
0.94
0.87
0.92
[ AA]
[ AA]
0.96
0.92

Aa

0.99
[ AA]
[ AA]
0.94
0.89
[ Aa]
0.91
[ Aa]
1.08
0.92
0.91
0.92
[ Aa]
[ Aa]

aa

Mean values for genotypes

0.45
0.87
0.86
0.48
0.49
0.48
0.47
0.45
0.44
0.45
0.49
0.45
0.44
0.45

Common
standard
deviation

H
0.58
[0]
0.44
[0]
[0]
[0]
0.43
0.59
0.52
0.61
0.02
0.61
0.54
0.61

Heritability

# most parsimonious model
[ ] denotes that the parameter was set and not estimated.
* indicates the model did not converge on its own. AA was set equal to 1 and aa set equal to 0 in order to estimate the model.

1
2
3
4
5
6
7
8
9
10
11
12
13
14

Model
Mixed
Sporadic
Multifactorial
Additive
Recessive
Dominant
Mixed-recessive
Mixed-dominant
Mixed free ’s * #
Mixed equal ’s
Recessive free ’s *
Recessive equal ’s
Dominant free ’s *
Dominant equal ’s

A allele
frequency

Table 3.5: Parameter estimates for segregation analysis of mother’s average gestational age of children in 96 multiplex families
(n=192 nonfounders).

Chapter 4: Considering rapidly evolving genes facilitates discovery of novel gene for
PTB: follicle-stuimulating hormone receptor, FSHR §
Abstract
The signals initiating parturition in humans have remained elusive, due to
divergence in physiological mechanisms between humans and model organisms typically
studied. Because of relatively large human head size and narrow birth canal crosssectional area compared to other primates, we hypothesized that genes involved in
parturition have evolved rapidly along the human and/or higher primate phylogenetic
lineages to decrease the length of gestation and alleviate complications arising from these
constraints. Consistent with our hypothesis, many genes involved in reproduction show
rapid evolution in their coding or adjacent noncoding regions. We screened >8,000 SNPs
in 150 rapidly evolving genes in 165 Finnish preterm and 163 control mothers for
association with PTB. A linkage disequilibrium block of SNPs in FSHR, rs11686474,
rs11680730 and rs12473870, showed significant association across ethnically diverse
populations. By considering rapid evolution, we identified a novel gene associated with
PTB, FSHR. We anticipate other rapidly evolving genes will similarly be associated with
PTB risk and elucidate essential pathways for human parturition.
Introduction
Because humans are born developmentally less mature than other mammals [124;
125], birth timing mechanisms may differ between humans and model organisms that
have been typically studied [126]. Evidence suggests that parturition has changed along
the human lineage in response to other uniquely human adaptations. The dramatic

§

This chapter is adapted from: Plunkett J, et al. Evolution History of FSHR in Humans
Predicts Role in Birth Timing. Submitted.
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increase in brain size, along with the human pelvis becoming narrower to facilitate
bipedalism, places unique constraints on birth in humans compared even with
evolutionarily close relatives such as Neanderthals and chimpanzees [127; 128]. Given
the historically high mortality rate associated with pregnancy, these human adaptations
are likely to have generated a strong selective pressure to initiate parturition at a
relatively earlier time in gestation compared to non-human primates to avoid
cephalopelvic disproportion and arrested labor. High rates of human versus non-human
primate divergence in human pregnancy-related genes, such as genes in the reproduction
Gene Ontology (GO) category [129; 130] as well as GO categories related to fetal
development, including transcription factors [131], nuclear hormone receptors [131],
transcriptional regulation [132] and development [130], support the notion that human
gestation length has been shortened to accommodate features unique to human
pregnancy. As a result, the set of genes rapidly evolving on the human lineage likely
includes genes that play important roles in regulating parturition and potentially influence
PTB risk.
Genetic influences on birth timing in humans appear to be substantial; however,
association studies using candidates selected from suspected pathways have not detected
robust susceptibility variants for PTB. Genome-wide association studies (GWAS) are
promising but will require large numbers of well-characterized subjects in order to
overcome the challenge of multiple statistical comparisons. To address these limitations,
we applied an evolutionarily-motivated filter to examine genes showing marked
divergence between humans and other mammals, defined by relative nucleotide
substitution rates in coding and highly conserved noncoding regions, for association with
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PTB. Here we show that genes with the signature of rapid evolution in humans provide
an informative group of candidates, and demonstrate as proof of concept that one rapidly
evolving gene, follicle-stimulating hormone receptor (FSHR), has significant association
with PTB.
Results and Discussion
Life history traits. Because of large human head size and narrow birth canal
cross-section compared to other primates [127], we hypothesized that genes involved in
parturition have evolved rapidly along the human phylogenetic lineage to decrease the
length of gestation and alleviate the complications arising from these constraints. We
performed a comparative analysis of life history traits in mammals to further evaluate
whether the relative gestational period in humans has decreased compared to other
primates and mammals. Data acquired by Sacher and Staffeldt [133] and reanalyzed by
us show that both adult and neonatal primates have higher brain to body weight ratios
compared to other mammals (Figure 4.1A, B). The decoupling of brain/body size ratios
in primates makes it possible to ask whether gestation in primates is linked to brain size
or body size. Primates and other mammals have equivalent gestational periods with
respect to brain weight (Figure 4.1C). In contrast, the gestational period in primates is
longer relative to the length of gestation in mammals with equivalent neonatal body
weights (Figure 4.1D). This suggests that the length of gestation is expected to change
with brain size but not body size.
Humans have evolved the highest adult brain to body weight ratio of any mammal
[29]. In contrast to the evolution of brain/body ratios along the lineage leading to
primates, the increase in the brain/body ratio along the lineage leading to humans is
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present in adults but not neonates (Figure 4.1B). The simplest explanation is that adult
brain/body ratios have changed independently of neonatal ratios. However, the ratio of
brain/body weight is highest at birth and declines until adulthood. Thus, an alternative
explanation is that both adult and neonatal brain/body ratios have increased in humans, as
in primates, but that a concurrent decrease in the length of gestation lowered the neonatal
brain/body ratio. This second possibility is supported by the relative immaturity of human
neonates compared to other primates [124; 125] and that the length of human gestation,
relative to either neonatal brain or body weight, is shorter than most other primates
(Figure 4.1C,D).
To examine the evolution of gestation length relative to neonatal brain and body
weight in primates, we inferred the evolution of these characters across a phylogenetic
tree. For both gestation-neonatal body ratio (Figure 4.2A) and gestation-neonatal brain
ratio (Figure 4.2B) there is a consistent trend of a relatively shorter length of gestation on
branches leading to humans. Of note, human has the lowest gestation-neonatal body ratio
(Figure 4.2A) or gestation-neonatal brain ratio (Figure 4.2B) of all the 20 primates. The
gestation-neonatal brain ratio for humans is 69% that of gorilla and 45% that of
chimpanzee. The gestation-neonatal body ratio of human is 49% that of gorilla and 50%
that of chimpanzee.
Signature of rapid evolution. In light of this evidence for human adaptation for
birth timing, we examined whether genes involved in parturition would display a
signature of positive selection, an increased rate of amino acid altering to synonymous
nucleotide substitutions (dN/dS; Figure 4.3). We found that, of 120 suggested candidate
genes for PTB [134] that were included in ENSEMBL database, 7 showed statistically
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significant increased rate acceleration (i.e. increased dN/dS; p<0.05) along the human
lineage in comparison to the other lineages. Table 4.1 shows these 7 genes plus 2
accelerated human genes significantly rapidly evolving along the human-chimpanzee
ancestor lineage (complete analysis of dN/dS reported in [135; 136]). Of these, common
variants of PGR [137] and MMP8 [138] have previously been found to contribute to PTB
risk. Of note, this candidate gene list derived from the Institute of Medicine report on
PTB [134], and information from the Gene Cards and Online Mendelian Inheritance in
Man databases was relatively enriched for genes rapidly evolving along the human
lineage compared to a normal distribution (3/120 expected; p=0.02) and exhibited a
similar trend for enrichment in comparison to other human genes in the ENSEMBL
database (408/10,440 observed with p<0.05; p=0.14 vs. suggested PTB candidates).
Using criterion agnostic to possible involvement with PTB, and measuring genome-wide
changes, we identified 175 genes either rapidly evolving along the human (40 genes) or
on the human and human-chimpanzee ancestor lineages combined (135 genes) at a 5%
false discovery rate (FDR) [139] from this analysis of protein-coding sequences.
Motivated by this evidence of protein coding region evolution for genes involved
in parturition and that positive selection has also been found to act on noncoding regions,
we developed a method to identify rapidly evolving noncoding sequences [132; 140]. We
identified a total of 401 elements significant along the human lineage and 2103 elements
significant along the human and human-chimpanzee ancestor lineages at a 5% FDR. To
choose candidate genes, we calculated gene-wise p-values for each gene locus by
assigning each conserved element to its nearest RefSeq gene [141] and a Fisher’s
combined p-value across the locus. This resulted in identification of a total of 279
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candidate genes (complete analysis of rapidly evolving non-coding regions reported in
[135; 136]). 150 of the genes identified as rapidly evolving in the protein-coding
sequence and highly conserved noncoding elements screens, selected based on expression
and functional information suggesting potential roles in parturition, were analyzed for
association with PTB (Table 4.2).
Association analysis of rapidly evolving genes. Because recent data suggests
that heritability of risk of PTB acts largely or exclusively through the maternal genome
[29; 30; 32] and the Finnish have low environmental risk and high genetic homogeneity
compared to other populations, we genotyped Finnish (165 preterm, 163 control) mothers
for 8,490 SNPs in the gene regions of our prioritized list of 150 rapidly evolving genes
(Figure 4.4). The most significant finding was rs6741370 (p=9.28 x 10-5) in the folliclestimulating hormone (FSH) receptor gene (FSHR). 91 SNPs were significant at the
p<0.01 level by allelic tests (Table 4.3). However, no SNPs were significant after
correcting for 6,042 independent tests, considering relationships among markers, by the
Bonferroni method (p<8.27 x 10-6). Of note, 8 of the 10 most statistically significant
SNPs were located in FSHR. We identified FSHR as rapidly evolving in the noncoding
analysis, with 40 changes in 4,218 bp of 17 conserved elements (human lineage p = 5.4 X
10-5). Moreover, FSHR was revealed as rapidly evolving in a study of noncoding
conserved elements by Prabhakar and colleagues [140], which otherwise had limited
overlap with our gene list (see Methods). FSHR also harbors SNPs with extreme iHS
values in the Yoruban population, reflecting extended haplotype homozygosity and
suggesting a recent selective sweep [142]. Bird and colleagues [143] identified a region
less than 1 megabase downstream of the FSHR gene boundaries as rapidly evolving in
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their study, further supporting rapid evolution of the locus. This information, together
with the known importance of variation in human FSHR in subfertility [144; 145], a risk
factor for preterm delivery independent of the use of assisted reproductive technologies
[146; 147], and evidence suggesting its expression in uterus and cervix [148-150],
motivated its specific study.
16 SNPs in FSHR showing potential association in the screening analysis (p<0.1)
were genotyped in US White (147 preterm, 157 control), US Black (79 preterm, 164
controls) and US Hispanic (73 preterm, 292 control) mothers (Figure 4.5; Table 4.4).
Several SNPs exhibited suggestive association (p<0.01) with PTB risk. One SNP in the
US Blacks, rs12473815, was significant after correcting multiple testing (13 independent
tests; p<0.004). The SNP rs12473815 is in high linkage disequilibrium (LD) with three
nearby SNPs, rs11686474, rs11680730 and rs12473870 (Figure 4.5), all of which showed
evidence of association across populations. Meta-analysis of these SNPs resulted in odds
ratios ranging from 1.37 to 1.41 with a common 95% confidence interval of 1.26-1.50. Of
note, when combining data from all populations tested by meta-analysis, p-values for
rs11686474 (p=0.0006) and rs11680730 (p=0.002) are significant after a Bonferroni
correction (p<0.003).
In FSHR, 4 SNPs in high LD show evidence of association with PTB across the
populations studied. These SNPs lie within intron 2 of FSHR (Figure 4.5) and show little
LD with variants outside of this intron, based on available information from the
International HapMap Project database [151]. Variants in this intron may tag yet
uncharacterized variants in coding regions or nearby regulatory sequences. Alternatively,
an intronic variant in FSHR may affect risk directly by altering functional sequences
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contained within the intron, such as microRNA binding sites, splice regulatory sites or
transcription regulation sites. For instance, a variant in a splice enhancer site may change
splicing patterns in favor of transcripts that promote PTB risk, as several alternatively
spliced FSHR isoforms have been observed with altered function [152]. Risk-promoting
variation in this gene likely contributes to birth timing, rather than size at birth, based on
additional tests examining gestational age or birth-weight Z-score as a quantitative trait,
rather than PTB affection status (Table 4.5). Hence, FSHR may represent a novel gene
involved in birth timing and PTB risk.
FSHR encodes the follicle-stimulating hormone (FSH) receptor. FSH is secreted
from the pituitary and, in females, acts primarily on receptors in the ovaries to stimulate
follicle development and synthesis of estrogens. Investigators also have observed FSHR
protein and mRNA expression in nongonadal tissues, including uterus and cervix [148150]. In these tissues, FSHR may mediate uterine relaxation, as suggested by FSH’s
ability to modify electrical signaling in the myometrium, independent of estrogen and
progesterone [148]. Padmanabhan and colleagues [153] noted a progressive rise in
bioactive serum FSH levels during pregnancy. Because high levels of FSH are known to
downregulate FSHR expression [154], increasing levels of FSH may lead to gradual
desensitization to the hormone and resultant increase in contractility as term approaches.
Additionally, evidence from the FSHR haploinsufficient mouse [155] suggests that FSHR
levels affect the relative abundance of progesterone receptor isoforms A (PR-A) and B
(PR-B). Increased PR-A: PR-B ratios, occurring in human pregnancy normally near term
and observed in FSHR haploinsufficient mice in non-pregnant states, are correlated with
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increased myometrium contractility. Hence, dysregulation of FSHR may contribute to
early uterine contractility and promote PTB.
Aspects of our approach pose limitations on interpretation of this work. First, we
assigned conserved elements to the nearest RefSeq gene to calculate gene-wise p-values;
however, conserved elements may not be associated with the nearest gene per se,
potentially affecting the accuracy of the estimated gene-wise p-values. Additionally,
because we use adjacent genes to estimate expected synonymous and nonsynonymous
rates for a given locus, rapidly evolving genes that are located physically nearby other
genes undergoing rapid evolution, such as gene families with multiple members in the
same region, may miss detection. The variability in number of probes represented on the
Affymetrix Genome-Wide Human SNP Array 6.0 within the gene regions of the 150
rapidly evolving genes tested poses another limitation. Although the coverage is adequate
for most rapidly evolving genes, there are some genes with too few probes tested to
support or refute their potential association with PTB; as a result, this study may have
failed to detect association between PTB and rapidly evolving genes underrepresented on
this genotyping array. Lastly, while precedence exists for intronic variants affecting
protein structure and function [156; 157], additional study is needed to determine whether
any of the SNPs associated with PTB in this work has a functional effect.
Overall, FSHR represents a likely candidate for involvement in PTB. Even though
FSHR has a plausible role in parturition physiology, it has not been considered in
previous association studies or appeared on candidate gene lists like that in the Institute
of Medicine report on PTB [134]. Thus, by considering rapid evolution, we identified a
gene associated with PTB that otherwise would not have been revealed by current models
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of parturition physiology. Moreover, our approach exploits an evolutionarily-motivated
filter to more efficiently utilize currently available datasets for PTB, which are probably
underpowered to detect variants of effect sizes reported in GWAS of other complex traits.
Our approach represents an alternative method for a priori gene discovery in which fewer
comparisons are made than in GWAS, thus potentially retaining more power to detect
effect sizes typical for common variants. We anticipate that other rapidly evolving genes
will similarly be associated with PTB risk and elucidate the essential pathways for human
parturition.
Materials and Methods
Allometric Analysis. Data acquired by Sacher and Staffeldt [133] was used to
examine the relationships among brain size, body size and gestation length among
mammalian species. Specifically, we compared logarithm-transformed values for these
traits between human, primate and non-primate mammals, using linear regression
implemented in R [158]. Additionally, we used allometric data from this paper and the
primate phylogeny delineated by Purvis [159] to trace the evolution of gestation-neonatal
body size ratio, and gestation-neonatal brain size ratio, using Mesquite [160]. Given a
phylogenic tree, the Mesquite method uses parsimony to reconstruct the ancestral states
by assuming a squared change for a continuous character from state x to state y is (x-y)2.
Coding sequence multiple sequence alignments. We obtained a set of 10,639
human gene predictions from the ENSEMBL database with one-to-one orthologs in the
chimpanzee, macaque, mouse, rat, dog, and cow genomes (Release 46) [161]. We limited
our analysis to only those proteins where the human, chimpanzee, macaque, and at least
75% of the mammalian genomes were present. To prevent spurious results arising from
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comparing different isoforms from different species, we compared all of the human gene
models against all of the chimpanzee gene models by BLAST searches, keeping the pair
with the highest percent identity (and longest gene model in case of tie). We then
compared this human gene model against all of the models from the other species,
finding the best match among the gene models in the other species. We generated a
multiple sequence alignment using the MUSCLE algorithm [162] and reverse translated
these alignments to generate nucleotide alignments. We limited our analysis to only those
proteins where the human, chimpanzee, macaque, and at least 75% of the mammalian
genomes were present. Chi-squared analysis was used to determine the statistical
significance of observed and expected genes with p<0.05 in suggested PTB candidate and
overall human gene lists.
Noncoding sequence multiple sequence alignments. We obtained a set of
highly conserved elements from UCSC Genome Browser [163]. In total, 443,061
noncoding sequences with a conservation score >=400 were tested. Of these elements,
34% overlapped coding sequence by at least one nucleotide and were excluded from the
analysis. The remaining noncoding elements span 47 MB (approximately 1.5% of the
genome). Therefore, these sequences represent only the most highly conserved noncoding
sequences and not the entire 6% of the noncoding genome that is functionally constrained
[164]. The median total branch length for these elements was 0.235, which is 1/4 the
synonymous rate. Therefore, these are not perfectly conserved sequences, but they are
evolving substantially slower than the neutral expectation. From the 17-way MultiZ
alignments that are publicly available (downloaded March 2007) [165], we extracted the
human, chimpanzee, macaque, mouse, rat, dog and cow sequences. We filtered this
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alignment set using two criteria. First, any alignment that contained 2 or more human
homoplasies (the human nucleotide was equal to a conserved nucleotide in the
mammalian outgroups, but different from the nucleotide shared between macaque and
chimpanzee) were removed. Second, if the human sequence had a paralog with a percent
difference less than twice the percent difference of the human-chimpanzee orthologs,
then that sequence was excluded (e.g. if the human-chimpanzee sequences were 98%
identical, the human paralog had to be less than 96% identical). This filter reduced the
chance that a rapidly evolving human sequence was actually a misaligned paralog.
Likelihood ratio tests. We used the phylogeny ( (Human, Chimpanzee),
Macaque), ( (Mouse, Rat), (Dog, Cow))). The evolutionary models were implemented in
the HYPHY package [166] and we used the Q-value software [139] to establish
statistical thresholds to achieve 5% false discovery rates (p-value distributions and pi_0
values in Figure 4.6). HYPHY creates a molecular evolution programming language,
enabling comparison of multiple evolutionary models and phylogenies. The source code
and documentation of the HYPHY tests is available from the Fay Laboratory.
For both tests, the alternative model has one additional degree of freedom and the
significance of the change in likelihood was determined using

2

statistics. Both models

use adjacent coding or conserved noncoding sequences to estimate the expectation for a
given sequence that accounts for variable mutation rates across the genome as well as
lineage-specific differences in effective population size by allowing for branch-specific
differences in selective constraint. For the coding sequence, we used 20 adjacent genes,
ten upstream and downstream when possible, to estimate the expected synonymous rate
and average constraints on each lineage. Twenty genes were used because the
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synonymous rate does vary across the genome in windows of approximately 10 MB
[167]. For noncoding sequences, we concatenated blocks of 25 kb of conserved
noncoding sequence. These blocks typically spanned about 1 MB of the genome. Each
element in the middle 50% of the window was tested against the expectation for that
window to limit edge effect. The window was then advanced to the element at the 50%
percentile of the window.
Previous studies of both coding [9, 46] and noncoding [11, 21] sequences identify
regions evolving under positive selection by a rate of evolution faster than a neutral rate.
However, we felt that this criterion is too restrictive since some genes may have an
increased rate of evolution along the human lineage relative to other mammals, but not
increased above the neutral rate. To include genes with a significantly increased rate in
humans compared to other mammals for testing in a population association study, we
identify genes as rapidly evolving by testing whether omega along the human (or
human+human-chimpanzee ancestor) lineage is significantly higher than omega along the
non-human lineages (or non-human+non-human-chimpanzee ancestor). Here, omega is
dN/dS-adj or dNC/dNC-adj, where dNC is the noncoding rate and dS-adj and dNC-adj
are the adjacent synonymous rates from the 10 upstream and 10 downstream genes and
the adjacent noncoding rates from 25 kb of conserved noncoding sequences, respectively.
Thus, we test whether the data is more likely under a model with 1 omega value or 2
omega values (Figure 4.3). The coding sequence model used the MG94xHKY85 [168]
model of codon evolution. The noncoding sequences model used an HKY85 model. We
calculated gene-wise p-values for each gene locus by assigning each conserved element
to its nearest RefSeq gene [141] and a Fisher’s combined p-value across the locus. Chi-
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squared analysis was used to determine the statistical significance of observed and
expected genes with p<0.05 in suggested PTB candidate and overall human gene lists.
Comparisons with published studies of rapid evolution. The following data
was extracted from published studies for comparison with results from our coding
analysis: genes with p<0.01 for test of dN/dS>1 from Nielson et al. [46]; genes with
p<0.01 for test of dN>dS on human lineage Clark et al. [9]; genes with adjusted p<0.05
for test of 1 omega versus 2 omegas (i.e. 1 on human lineage, 1 for other species) Arbiza
et al [48]. For comparison with results from our noncoding analysis, we compared closest
genes to human accelerated regions listed in Table S7 of Pollard et al. [11] and closest
genes to regions in listed in Table S1 of Prabhakar et al [21]. Ensembl gene identification
numbers and/or HUGO Gene Nomenclature Committee (HGNC) gene symbols, as
available, were compared among studies to determine the degree of overlap. The Venny
[169] online tool was used to visually represent the degree of overlap among studies as
Venn diagrams (Figures 4.7 and 4.8).
Our list of rapidly evolving coding region gene list showed low overlap with
previous studies that required for dN/dS > 1 in their analyses (6% with Clark et al. [130],
0% Nielson et al. [170]) and more overlap with Arbiza et al. [171] (26%), which
considered rate acceleration on the human lineage by methods more similar to ours than
those used by [130; 170] (Figure 4.7). For rapidly evolving conserved noncoding
elements in humans, 22% of the elements we identified were in common with Prabhakar
et al. [140]. Considering unique genes associated with rapidly evolving conserved
noncoding elements in humans, 11% of our genes also were identified by Prabhakar et al.
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[140], and 4% identified by Pollard et al. [132]. Similar to our study, 4% of unique genes
in the Prabhakar study overlapped with those identified by Pollard et al. (Figure 4.8).
Candidate rapidly evolving gene list. To minimize the number of tests we
would perform and thereby retain more power to detect small effects, we selected a
subset of genes likely to be involved in parturition, based on expression and functional
information, to use as candidate genes. A candidate gene list was developed using genes
identified as rapidly evolving from following categories: 10% FDR human lineage from
coding screen, 10% FDR human lineage from noncoding screen and 5% FDR humanchimpanzee lineage from coding screen. A total of 742 genes are included in this
comprehensive list of rapidly evolving genes. To minimize the number of tests we would
perform and thereby retain more power to detect small effects, we selected a subset of
genes likely to be involved in parturition, based on expression and functional
information, to use as candidate genes. Genes were included as candidates if at least 2 of
3 conditions met: had a GO term suggesting possible biological role in parturition (e.g.
extracellular matrix, calcium ion, DNA-binding/transcription, intracellular signaling, cell
fate/apoptosis, cell growth); were previously identified as candidate gene; had expression
included relevant tissues (e.g. uterus, placenta, brain) documented in Unigene [172].
Duplicated genes from a list developed by Bailey and colleagues [173] that were
identified as pregnancy, fetal, placental or hormone-related genes were also included as
candidates. A total of 150 of genes were used as candidate genes in subsequent analysis
(Table 4.2).
Human Subjects. Mothers of preterm or term infants were enrolled for genetic
analysis by methods approved by Institutional Review Boards/Ethics Committees at each
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participating institution. Informed consent was obtained for all participants. Mothers with
PTB were included if the birth was spontaneous (non-iatrogenic), singleton, had no
obvious precipitating stimulus (trauma, infection, drug use), and was less the 37 weeks
(Yale University; New York University) or 36 weeks (University of Helsinki; University
of Oulu; Centennial Hospital, Nashville, TN) of completed gestation. DNA from blood or
saliva was prepared by standard methods. Race/ethnicity was assigned by self-report. For
the US Black cohort, no differences in were found in the distribution of 24 ancestry
informative markers selected across the genome comparing cases and controls (data not
shown). All specimens were linked with demographic and medical data abstracted from
maternal/neonatal records.
Genotyping. Initial genotyping of the Finnish cohort was performed using the
Affymetrix® Genome-Wide Human SNP Array 6.0. Genotypes were called from cell
intensity data by the birdseed v2 algorithm, implemented in Affymetrix® Genotyping
Console 3.0. Of 428 SNP 6.0 arrays available for analysis, only 392 samples had their
raw intensity data converted to genotype calls using the birdseed v2 algorithm in
Affymetrix Genotype Console 3.0, after poor quality chips (i.e. “out of bounds”
designation or XY gender call by Genotyping Console) were excluded. We selected
SNPs within the gene regions, defined as 5 kilobases (kb) upstream to 5 kb downstream
of the most inclusive gene boundaries between those listed for the longest transcript
documented in the Ensembl database and those defined in our comparative genomic
analysis, of our 171 rapidly evolving candidate genes for analysis. A total of 12,444
SNPs were located within our rapidly evolving genes. The gene coverage ranged from 0900 SNPs/gene region, with a median of 13 SNPs/gene region. 11 genes had no SNPs in
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the gene region represented on the SNP 6.0 array. Genotyping for additional analysis of
the Finnish cohort and replication analysis was performed using the Sequenom iPLEX
massARRAY technology (Sequenom, San Diego, CA).
Finnish cohort analysis. Data cleaning was performed with the Whole-genome
Association Study Pipeline (WASP) software package [174] and PLINK [175]. An
additional 6 individuals were excluded because of possible cryptic relatedness, as
suggested by their presence in IBS distance-defined clusters far from the rest of the
genotyped subjects. 58 individuals were removed due to a high genotype missing rate for
the SNPs of interest (i.e. <95% call rate), leaving a total of 165 preterm and 163 control
mothers in the final analysis. Of 12,444 SNPs selected, 9,610 SNPs were used in the final
analysis after removing SNPs not in Hardy-Weinberg Equilibrium in controls (p<0.001),
<95% genotype call rate, with minor allele frequency<0.05 or were duplicate probes.
Allelic ( 2, df 1) and genotypic ( 2, df 2) tests for association, LD measures and odds
ratios were estimated for each cohort using WASP and/or PLINK. Our primary analysis
considered PTB affection status (i.e. delivery <36 weeks) as a binary trait, comparing
allele and genotype frequencies between case and control groups by

2

test. We also

examined gestational age and birth-weight Z-score as quantitative traits, standardized to
normal distributions ( =0, =1) using a Wald test to compare the mean phenotype
between different allele or genotype classes.
A variety of measures were taken to ensure that results from these test were
explained by true associations. First, genomic control measures of population
substructure ( =1.07) indicated little inflation of statistics due to substructure. Correction
for IBS clustering to bring

to 1 resulted in the same SNPs being found as most
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significantly associated, suggesting that whatever minor population substructure may
exist does not explain the association findings. Confounding of the results due to
genotyping batch or location effects was not observed. Furthermore, minor allele
frequencies observed in controls were generally consistent with HapMap estimates for
Caucasians. As some SNPs are expected to show significant association with PTB by
chance due to the large number of tests we are performing, we corrected for multiple
testing using the simpleM method [176], which estimates the number of independent
tests, given the LD relationships among SNPs, used to adjust the significance level.
Extension of genotyping in Finnish cohort. Because FSHR showed evidence of
enrichment of significant p-values as well as representing a plausible agent in parturition,
we chose to examine the genes in greater depth. Of the 149 SNPs tested in FSHR in the
Affymetrix analysis, 22 showed evidence of association (p<0.01) in the SNP 6.0 analysis
and 9 were genotyped with the Sequenom technology for cross-platform validation. SNP
genotypes showed high degree of concordance across platforms (~98%) and association
results were consistent.
To increase coverage, we genotyped an additional 42 SNPs spanning the FSHR
gene region in a subset of the Finnish cohort (n= 105 preterm, 95 control mothers) based
on DNA availability and quality. For SNP selection, data from the HapMap CEU
population was examined in the Haploview program [177], using tagger and haplotype
block functions, to identify regions of high LD. We selected 1 SNP per haplotype block,
defined using the D’ confidence interval method [178], having the highest minor allele
frequency (MAF) in the CEU population for genotyping. We also included coding SNPs
and SNPs to improve coverage of conserved elements contributing to the gene’s
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designation as “rapidly evolving.” This selection scheme resulted in approximately 2030% coverage of the gene region at r2≥0.8. Data cleaning and analysis was conducted as
described above. In total, 40 SNPs met quality control standards (Hardy-Weinberg
Equilibrium in controls p>0.001, >95% call rate, MAF>0.01) and were analyzed. Of the
SNPs genotyped to increase coverage, those that showed suggestive association (p<0.1;
n=16) were examined further.
Replication Analysis. 16 SNPs in FSHR showing potential association in the
screening analysis (p<0.1) were genotyped in US White (147 preterm, 157 control), US
Black (79 preterm, 164 controls) and US Hispanic (73 preterm, 292 control) mothers
(Figure 4.4; Table 4.4). Data cleaning and analysis was performed as described above.
Meta-analysis of data for significant SNPs was done using the Mantel-Haenszel method,
after successfully passing the test of homogeneity.

78

Figure 4.1. Allometric analysis of brain size, body size, and gestational length by
linear regression.

Brain to body weight ratios for adults (A) and neonates (B) are shown for humans (red),
other primates (blue), and other mammals (black). The black line shows least squares fits
to the 91 mammalian species. Neonatal brain (C) and body size (D) to gestational time
ratios are displayed for the same species. The blue line shows least squares fits to 15
primate species. Allometric data was acquired by Sacher and Staffeldt (1974).
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Figure 4.2A. Phylogenetic analysis of brain size, body size, and gestational length in
primates.

Gestational time to neonatal brain size natural logarithm-transformed ratios are shown for each species and
color coded along each lineage as inferred by parsimony. Allometric data was acquired by Sacher and
Staffeldt (1974) and phylogeny by Purvis (1995)
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Figure 4.2B. Phylogenetic analysis of brain size, body size, and gestational length in
primates.

Gestational time to neonatal body size natural logarithm-transformed ratios are shown for each species and
color coded along each lineage as inferred by parsimony. Allometric data was acquired by Sacher and
Staffeldt (1974) and phylogeny by Purvis (1995) .
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For each gene of interest, we use the ten upstream and downstream genes to estimate a regional synonymous rate (dSr) and the
expected lineage-specific constraint scaling factors (a). These scaling factors take into account that the constraint on each lineage will
vary due to the effective population size and other species-specific parameters. Using these regional parameters, a gene-specific dN/dS
ratio (w) is estimated. In this case, the lineage of interest leads to extant species C. In the null model, the nonsynonymous substitution
rate is estimated as aCwndSr. This is compared to the alternative model, where nonsynonymous branch length is set to a free
parameter (R).

Figure 4.3: A likelihood ratio test to identify lineage-specific constraints.

Figure 4.4. Flowchart representing study design for testing association of rapidly
evolving genes with preterm birth.
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The gene structure for FSHR is represented by an arrow in which black rectangles designate 3’ and 5’ untranslated regions and dark grey
rectangles designate coding exons. Diamonds represent SNPs on the Affymetrix SNP 6.0 array examined in the Finnish cohort. Triangles represent
SNPs tested in the replication cohorts. A star indicates rs12473815, which is significant after multiple testing correction in US Blacks (p<0.004).
Circles represent conserved elements examined in the region.

Figure 4.5. Overview of the SNPs tested in the FSHR gene region.

Figure 4.6: Distributions of p-values for coding and noncoding screens used to
determine false discovery rate thresholds for significance.

Panel A depicts the distribution of p-values for test for significant rate acceleration on
human lineage compared to other mammalian lineages for coding sequences. Panel B
depicts the distribution of p-values for test for significant rate acceleration on humanchimpanzee lineage compared to other mammalian lineages for coding sequences. Panel
C depicts the distribution of gene-wise p-values for test for significant rate acceleration
on human lineage compared to other mammalian lineages for noncoding sequences.
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Figure 4.7: Venn diagram illustrating the overlap between the results of our coding
analysis and similar studies.

Genes identified by Arbiza et al. (2006), Clark et al. (2003), Nielson et al. (2005) are
compared to genes we identified as rapidly evolving on the human lineage (10% FDR,
Panel A) or on the human+human-chimpanzee ancestor lineage (5% FDR, Panel B).
Panel C depicts the overlap between genes we identified as rapidly evolving on the
human lineage (10% FDR) or on the human+human-chimpanzee ancestor lineage (5%
FDR).
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Unique genes identified by Pollard et al. (2006) and Prabhakar et al. (2006) are compared to genes we identified as rapidly evolving
on the human lineage (10% FDR).

Figure 4.8: Venn diagram illustrating the overlap between the results of our noncoding analysis and similar studies.
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Oxytocin-neurophysin 1 precursor
Prostaglandin E2 receptor, EP4
Estrogen receptor
Orphan nuclear receptor TR2
Neurotrophin-3 precursor
Oxytocin receptor
Progesterone receptor
Pregnancy-associated plasma protein-A
Matrix metalloproteinase-8

Expected
Ratioa
0.25
0.49
0.22
0.36
0.29
0.13
0.24
0.30
0.51

pvalueb
0.017
0.018
0.020
0.024
0.042
0.048
0.048
0.099
0.230

Human-chimpanzee ancestor
Expected Observed p-valueb
Ratioa
Ratio
0.16
0.37
0.546
0.33
0.33
0.539
0.15
0.13
0.216
0.24
0.22
0.818
0.26
0.15
0.439
0.16
0.20
0.168
0.27
0.31
0.127
0.22
0.34
1.79x10-8
0.54
0.83
3.94x10-4

b

The ratio reported is the ratio of the nonsynonymous to synonymous substitutions (dN/dS) for coding sequence.
The p-value reported is from the likelihood ratio test comparing the rate on the human or the human plus the human-chimpanzee
ancestral lineage to the expected rate from the background model.
c
Gene identified as rapidly evolving by Arbiza and colleagues (2006).
d
Gene also was identified as rapidly evolving by Clark and colleagues (2003).

a

OXT
PTGER4c
ESR1
NR2C1
NTF3d
OXTR
PGR d
PAPPA d
MMP8

Gene

Human
Observed
Ratio
1.47
1.10
0.55
0.93
0.60
0.43
0.68
0.29
0.67

Table 4.1. Sample of candidate genes showing rapid coding region evolution in humans.

Table 4.2: Candidate rapidly evolving genes examined for association with preterm
birth.
Gene

Ensembl ID

Chromosome

ENSG00000187980
ENSG00000054118
ENSG00000197587
ENSG00000134245
ENSG00000163554
ENSG00000133055
ENSG00000133063
ENSG00000117335
ENSG00000162814
ENSG00000143771
ENSG00000183814
ENSG00000084674
ENSG00000170820
ENSG00000028116
ENSG00000168758
ENSG00000196228
ENSG00000125571
ENSG00000183840
ENSG00000169554
ENSG00000183091
ENSG00000138399
ENSG00000138435
ENSG00000064933
ENSG00000013441
ENSG00000116117
ENSG00000163283
ENSG00000163286
ENSG00000157985
ENSG00000168387
ENSG00000189283
ENSG00000196353
ENSG00000169744
ENSG00000145241
ENSG00000083857
ENSG00000205096
ENSG00000174358
ENSG00000171540
ENSG00000164292
ENSG00000170482
ENSG00000204956

PLA2G2C
THRAP3
DMBX1
WNT2B
SPTA1
MYBPH
CHIT1
CD46
SPATA17
CNIH4
LIN9
APOB
FSHR
VRK2
SEMA4C
SULT1C3
IL1F7
GPR39
ZEB2
NEB
FASTKD1
CHRNA1
PMS1
CLK1
PARD3B
ALPP
ALPPL2
CENTG2
ASB14
FHIT
CPNE4
LDB2
CENPC1
FAT
DUX4_HUMAN
SLC6A19
OTP
RHOBTB3
SLC23A1
PCDHGA1

1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
4
4
4
4
5
5
5
5
5
89

Gene region
start (bp)A
20,358,071
36,457,626
46,693,885
112,804,363
156,842,020
201,398,562
201,436,600
205,987,025
215,879,672
222,606,183
224,480,481
21,072,806
48,936,801
57,432,980
96,884,204
108,123,399
113,382,017
132,885,617
144,811,277
152,045,110
170,089,515
175,316,097
190,352,355
201,411,164
204,824,164
232,931,318
232,975,096
235,971,127
57,252,242
59,361,681
132,731,274
15,988,937
68,015,584
187,740,918
191,214,485
1,249,710
76,948,651
95,087,606
138,722,343
140,685,388

Gene region
stop (bp)
20,379,247
36,547,744
46,769,955
112,872,035
156,928,130
201,416,565
201,496,865
206,040,481
216,238,784
222,638,777
224,577,619
21,334,249
49,262,724
58,284,303
96,905,699
108,265,257
113,412,506
133,125,602
145,811,772
152,304,406
170,147,595
175,359,048
190,508,863
201,442,667
206,193,781
232,959,619
233,011,310
236,715,338
57,297,334
60,575,887
133,593,392
16,703,648
68,104,114
188,341,814
191,232,642
1,281,385
76,999,618
95,162,827
138,751,981
140,698,003

ENSG00000173210
ENSG00000065029
ENSG00000180872
ENSG00000135346
ENSG00000164520
ENSG00000048052
ENSG00000196335
ENSG00000105954
ENSG00000091138
ENSG00000178234
ENSG00000156006
ENSG00000120907
ENSG00000198363
ENSG00000064218
ENSG00000153707
ENSG00000106829
ENSG00000156345
ENSG00000182752
ENSG00000167123
ENSG00000165997
ENSG00000095794
ENSG00000165731
ENSG00000095587
ENSG00000166407
ENSG00000166961
ENSG00000149021
ENSG00000173153
ENSG00000204571
ENSG00000118113
ENSG00000204403
ENSG00000137713
ENSG00000064309
ENSG00000111266
ENSG00000123360
ENSG00000110958
ENSG00000151846
ENSG00000150893
ENSG00000174126
ENSG00000139842
ENSG00000092054
ENSG00000196792
ENSG00000151322
ENSG00000136352
ENSG00000198807
ENSG00000184302

ABLIM3
ZNF76
DEFB112
CGA
RAET1E
HDAC9
STK31
NPVF
SLC26A3
GALNT11
NAT2
ADRA1A
ASPH
DMRT3
PTPRD
TLE4
CCRK
PAPPA
CEECAM1
ARL5B
CREM
RET
TLL2
LMO1
MGC35295
SCGB1A1
ESRRA
KRTAP5-11
MMP8
CASP12
PPP2R1B
CDON
DUSP16
PDE1B
PTGES3
PABPC3
FREM2
ENSG00000174126
CUL4A
MYH7
STRN3
NPAS3
NKX2-1
PAX9
SIX6
90

5
6
6
6
6
7
7
7
7
7
8
8
8
9
9
9
9
9
9
10
10
10
10
11
11
11
11
11
11
11
11
11
12
12
12
13
13
13
13
14
14
14
14
14
14

148,496,326
35,330,427
50,131,694
87,847,192
150,246,014
18,279,517
23,711,404
25,213,311
107,188,393
151,348,797
18,280,063
26,662,251
62,573,374
961,964
8,145,485
81,284,764
89,766,183
117,840,886
130,201,775
18,983,319
35,450,807
42,796,962
98,109,356
8,197,433
60,276,052
61,938,099
63,824,620
70,963,408
102,083,599
103,980,451
111,097,898
125,320,174
12,513,420
53,224,671
55,338,379
24,563,276
38,058,234
40,907,081
112,906,151
22,947,820
30,427,761
32,428,709
35,997,916
36,195,877
60,034,147

148,625,192
35,376,740
50,461,861
87,893,643
150,258,863
19,021,186
23,843,843
25,256,794
107,275,261
151,463,085
18,341,561
26,968,234
63,945,182
986,732
10,571,307
81,955,007
89,784,487
118,209,421
130,253,724
19,274,735
35,546,892
42,950,850
98,268,658
8,345,763
60,305,780
62,054,461
63,845,786
70,987,532
102,105,868
104,254,354
111,156,373
125,512,554
12,632,500
53,264,290
55,373,318
24,575,705
38,379,883
40,917,746
112,984,825
22,987,727
30,570,340
33,386,974
36,065,064
36,683,420
60,062,098

ENSG00000140009
ENSG00000100815
ENSG00000182256
ENSG00000198838
ENSG00000154237
ENSG00000131650
ENSG00000183632
ENSG00000102962
ENSG00000050820
ENSG00000186153
ENSG00000070444
ENSG00000006047
ENSG00000133020
ENSG00000141048
ENSG00000125414
ENSG00000176160
ENSG00000213218
ENSG00000136488
ENSG00000136487
ENSG00000189162
ENSG00000171634
ENSG00000089685
ENSG00000181409
ENSG00000186765
ENSG00000101605
ENSG00000101489
ENSG00000133313
ENSG00000131196
ENSG00000174837
ENSG00000132024
ENSG00000127507
ENSG00000189231
ENSG00000131113
ENSG00000170848
ENSG00000170853
ENSG00000124435
ENSG00000204941
ENSG00000008438
ENSG00000105499
ENSG00000104826
ENSG00000104827
ENSG00000189052
ENSG00000213030
ENSG00000196337
ENSG00000171101

ESR2
TRIP11
GABRG3
RYR3
LRRK1
KREMEN2
TP53TG3
CCL22
BCAR1
WWOX
MNT
YBX2
MYH8
MYH4
MYH2
HSF5
CSH3
CSH2
GH2
CSH1
BPTF
BIRC5
AATK
FSCN2
MYOM1
BRUNOL4
CNDP2
NFATC1
EMR1
CC2D1A
EMR2
PSG3
PSG1
PSG6
PSG11
PSG2
PSG4
PGLYRP1
PLA2G4C
LHB
CGHB_HUMAN
CGHB_HUMAN
CGB
CGB7
SIGLECP3
91

14
14
15
15
15
16
16
16
16
16
17
17
17
17
17
17
17
17
17
17
17
17
17
17
18
18
18
18
19
19
19
19
19
19
19
19
19
19
19
19
19
19
19
19
19

63,556,569
91,500,614
24,794,429
31,385,469
99,271,983
2,949,218
32,546,984
55,930,968
73,815,429
76,653,469
2,229,115
7,127,322
10,229,495
10,280,658
10,360,323
53,847,530
59,298,106
59,298,288
59,306,304
59,343,295
63,206,700
73,714,361
76,700,703
77,105,153
3,051,806
33,072,000
70,309,577
75,266,605
6,833,582
13,873,014
14,699,205
47,912,635
48,044,852
48,093,080
48,198,649
48,255,202
48,358,736
51,209,255
53,237,916
54,206,049
54,212,940
54,233,875
54,237,709
54,244,344
56,357,397

63,824,462
91,581,139
25,456,729
31,950,591
99,432,838
2,963,381
32,574,764
55,962,600
73,864,452
77,833,566
2,256,834
7,143,598
10,271,188
10,318,846
10,433,169
53,925,744
59,309,848
59,332,647
59,317,955
59,354,930
63,416,200
73,738,310
76,759,467
77,119,582
3,215,106
34,124,249
70,344,336
75,440,665
6,908,102
13,907,691
14,755,353
47,941,508
48,080,711
48,118,883
48,227,471
48,283,665
48,406,630
51,223,144
53,310,865
54,217,159
54,224,444
54,245,378
54,249,212
54,258,929
56,395,399

ENSG00000131848
ENSG00000125780
ENSG00000101452
ENSG00000064655
ENSG00000101181
ENSG00000060491
ENSG00000154640
ENSG00000157554
ENSG00000100302
ENSG00000188677
A

ZSCAN5
TGM3
DHX35
EYA2
GTPBP5
OGFR
BTG3
ERG
RASD2
PARVB

19
20
20
20
20
20
21
21
22
22

61,415,347
2,216,426
37,019,406
44,941,086
60,186,496
60,901,622
17,882,811
38,670,792
34,223,536
42,721,506

61,576,564
2,274,202
37,243,569
45,255,897
60,216,218
60,920,797
17,949,761
38,990,795
34,284,987
42,901,434

Positions refer to NCBI36 (hg18, March 2006 assembly) build of the human genome.
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SNP
Affymetrix
Probe ID
SNP_A8453479
SNP_A2214277
SNP_A8574083
SNP_A1963108
SNP_A8393579
SNP_A1925725
SNP_A2259062
SNP_A8693449
SNP_A4232093
SNP_A8574095
SNP_A1795584
SNP_A1963125
FSHR
FSHR
FSHR
FSHR
FSHR
FSHR

ENSG00000170820

ENSG00000170820

ENSG00000170820

ENSG00000170820

ENSG00000170820

ENSG00000170820

FSHR

ENSG00000170820

FSHR

FSHR

ENSG00000170820

ENSG00000170820

FSHR

ENSG00000170820

FSHR

FSHR

ENSG00000170820

ENSG00000170820

Gene
Symbol

Ensembl Gene ID

2

2

2

2

2

2

2

2

2

2

2

2

49,131,327

49,124,921

49,119,336

49,098,912

48,967,735

48,954,639

48,951,679

48,949,643

48,947,479

48,946,762

48,945,764

48,937,400

Chromosome Location
(bp) A

0.02
0.0026

5.98x10-4

6.44x10-4
0.0060

8.08x10-5

0.0015

0.0016

6.78x10-4
3.94x10-4

0.0042

0.0063

0.0031

0.03

0.0036

0.0079

0.0078

Genotypic
P-value

0.0045

0.0020

0.0034

0.0074

0.0021

0.0087

0.0052

Allelic Pvalue

0.58 (0.43-0.79)

0.64 (0.47-0.88)

2.35 (1.53-3.63)

2.36 (1.45-3.84)

0.56 (0.40-0.78)

1.58 (1.15-2.17)

0.43 (0.25-0.75)

1.60 (1.17-2.20)

0.36 (0.16-0.78)

0.54 (0.36-0.80)

0.59 (0.40-0.88)

0.47 (0.27-0.81)

Odds Ratio

Table 4.3: SNPs in the rapidly evolving gene regions tested with p-values <0.01 in the Finnish cohort (n=165 cases, 163
controls).
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SNP_A2119506
SNP_A2187829
SNP_A8694413
SNP_A1872585
SNP_A4275652
SNP_A1963128
SNP_A4261924
SNP_A8574097
SNP_A2171016
SNP_A2081721
SNP_A2248307
SNP_A8574895
SNP_A8399741
SNP_A2183124
SNP_A8437696
FSHR
VRK2
CENTG2
CENTG2
CENTG2

ENSG00000170820

ENSG00000028116

ENSG00000157985

ENSG00000157985

ENSG00000157985

FSHR

ENSG00000170820

FSHR

FSHR

ENSG00000170820

ENSG00000170820

FSHR

ENSG00000170820

FSHR

FSHR

ENSG00000170820

ENSG00000170820

FSHR

ENSG00000170820

FSHR

FSHR

ENSG00000170820

ENSG00000170820

FSHR

ENSG00000170820

2

2

2

2

2

2

2

2

2

2

2

2

2

2

2

236,156,777

236,137,704

236,112,093

57,597,195

49,227,555

49,219,551

49,210,919

49,194,560

49,184,796

49,184,353

49,184,334

49,145,866

49,145,845

49,141,564

49,141,487

0.0013

0.0019

0.0028

0.0046

0.0054

0.0089

0.0062

0.0062

0.0011

0.0057

0.0065

0.0071

0.02

0.02

0.03

0.02

0.0094

0.0042

0.0026

0.0021

6.81 x10-4

5.94 x10-4

0.0010

3.38 x10-4

0.0042

0.0014

3.92 x10-4

0.0011

9.92 x10-4

2.72 x10-4

1.67 (1.22-2.29)

1.64 (1.20-2.24)

1.73 (1.21-2.48)

1.91 (1.21-3.00)

1.86 (1.20-2.90)

1.77 (1.15-2.73)

1.82 (1.18-2.82)

1.82 (1.18-2.82)

1.97 (1.31-2.98)

1.75 (1.27-2.41)

1.97 (1.31-2.97)

1.76 (1.27-2.45)

1.82 (1.31-2.52)

1.80 (1.30-2.49)

1.82 (1.32-2.52)
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SNP_A8560303
SNP_A8624292
SNP_A8444000
SNP_A4242521
SNP_A8383162
SNP_A8558654
SNP_A1910513
SNP_A8498171
SNP_A8689355
SNP_A2298264
SNP_A2095659
SNP_A4203581
SNP_A8694222
SNP_A4251667
SNP_A1795008
FHIT
FHIT
FHIT
CPNE4
CPNE4

ENSG00000189283

ENSG00000189283

ENSG00000189283

ENSG00000196353

ENSG00000196353

FHIT

ENSG00000189283

FHIT

FHIT

ENSG00000189283

ENSG00000189283

FHIT

ENSG00000189283

FHIT

FHIT

ENSG00000189283

ENSG00000189283

FHIT

ENSG00000189283

FHIT

FHIT

ENSG00000189283

ENSG00000189283

FHIT

ENSG00000189283

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

133,390,995

133,390,589

60,478,506

60,478,478

60,475,589

60,473,008

60,136,687

60,120,766

59,966,929

59,897,057

59,896,687

59,893,263

59,879,851

59,878,852

59,763,565

0.0030

0.0058

0.0021

0.0014

0.0097

0.0053

0.0076

0.0073

0.0051

0.0050

0.0039

0.0064

0.0076

0.0082

0.0085

0.0030

0.0033

0.0067

0.0053

0.0076

0.0041

0.02

0.03

0.02

0.01

0.0096

0.0042

0.02

0.04

0.03

1.59 (1.17-2.17)

1.55 (1.13-2.11)

0.45 (0.27-0.76)

0.42 (0.24-0.72)

1.65 (1.13-2.41)

1.74 (1.18-2.58)

1.52 (1.12-2.07)

1.53 (1.12-2.08)

0.49 (0.29-0.81)

0.64 (0.47-0.88)

0.63 (0.47-0.86)

0.65 (0.48-0.89)

0.65 (0.48-0.89)

2.76 (1.26-6.04)

0.56 (0.37-0.87)
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SNP_A2247251
SNP_A2144689
SNP_A1932424
SNP_A1906715
SNP_A8412574
SNP_A8318381
SNP_A4281442
SNP_A8620026
SNP_A8502613
SNP_A8672025
SNP_A8478172
SNP_A1802900
SNP_A8620032
SNP_A8582336
SNP_A1892692
LDB2
LDB2
LDB2
LDB2
RHOBTB3

ENSG00000169744

ENSG00000169744

ENSG00000169744

ENSG00000169744

ENSG00000164292

LDB2

ENSG00000169744

LDB2

LDB2

ENSG00000169744

ENSG00000169744

CPNE4

ENSG00000196353

LDB2

CPNE4

ENSG00000196353

ENSG00000169744

CPNE4

ENSG00000196353

LDB2

CPNE4

ENSG00000196353

ENSG00000169744

CPNE4

ENSG00000196353

5

4

4

4

4

4

4

4

4

4

3

3

3

3

3

95,145,598

16,460,122

16,400,295

16,128,817

16,104,049

16,088,861

16,086,960

16,027,754

16,020,079

16,007,023

133,450,246

133,421,585

133,406,698

133,404,646

133,398,962

0.0071

0.0090

0.0048

0.0040

0.0022

0.0048

0.0039

0.0025

0.0071

0.0093

0.0098

0.0060

0.0073

0.0079

0.0079

0.02

0.03

0.0030

0.02

0.0071

0.01

0.01

0.0091

0.01

0.01

0.0056

0.02

0.02

0.02

0.02

0.56 (0.37-0.86)

0.65 (0.48-0.90)

2.27 (1.27-4.08)

0.61 (0.43-0.85)

1.67 (1.20-2.32)

1.61 (1.15-2.24)

1.65 (1.17-2.31)

1.63 (1.19-2.23)

1.62 (1.14-2.30)

1.59 (1.12-2.25)

1.50 (1.10-2.04)

0.61 (0.43-0.87)

0.62 (0.44-0.88)

0.62 (0.44-0.89)

0.62 (0.44-0.89)
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SNP_A2273250
SNP_A1921353
SNP_A1874035
SNP_A1874540
SNP_A1996956
SNP_A4213521
SNP_A4258746
SNP_A1840834
SNP_A2067220
SNP_A2031381
SNP_A1850261
SNP_A8519096
SNP_A1782188
SNP_A4291855
SNP_A4294654
LMO1
LMO1
DUSP16
NPAS3
PAX9

ENSG00000166407

ENSG00000166407

ENSG00000111266

ENSG00000151322

ENSG00000198807

PTPRD

ENSG00000153707

LMO1

PTPRD

ENSG00000153707

ENSG00000166407

PTPRD

ENSG00000153707

LMO1

PTPRD

ENSG00000153707

ENSG00000166407

PTPRD

ENSG00000153707

PTPRD

CGA

ENSG00000135346

ENSG00000153707

RHOBTB3

ENSG00000164292

14

14

12

11

11

11

11

9

9

9

9

9

9

6

5

36,499,281

32,907,061

12,629,753

8,286,416

8,286,194

8,285,769

8,285,210

99,677,160

99,670,770

81,636,214

81,635,796

8,687,215

8,522,140

87,865,333

95,152,785

0.0040

9.83 x10-4

0.0075

0.0080

0.0014

0.0045

0.0033

0.0033

0.0043

0.03

0.0061

0.0018

0.02

0.02

0.02

0.02

0.0040

0.0023

3.70 x10-4

9.83 x10-4

0.04

0.0087

0.0056

0.0041

5.19 x10-4
0.0053

0.0075

0.02

0.0029

0.0071

1.91 (1.18-3.07)

1.61 (1.13-2.28)

0.59 (0.43-0.82)

1.60 (1.16-2.22)

1.63 (1.18-2.26)

1.63 (1.18-2.26)

1.60 (1.16-2.22)

1.68 (1.23-2.29)

1.68 (1.23-2.29)

0.56 (0.41-0.77)

0.59 (0.40-0.88)

1.79 (1.18-2.70)

0.42 (0.25-0.69)

1.74 (1.21-2.51)

0.56 (0.37-0.86)

98

SNP_A8513359
SNP_A8382205
SNP_A2263150
SNP_A8488733
SNP_A2192706
SNP_A8494398
SNP_A8686463
SNP_A2305114
SNP_A8606414
SNP_A2193067
SNP_A8366136
SNP_A8309208
SNP_A8653985
SNP_A4246524
SNP_A2019253
WWOX
WWOX
WWOX
EMR1
ERG

ENSG00000186153

ENSG00000186153

ENSG00000186153

ENSG00000174837

ENSG00000157554

GABRG3

ENSG00000182256

WWOX

GABRG3

ENSG00000182256

ENSG00000186153

GABRG3

ENSG00000182256

GABRG3

GABRG3

ENSG00000182256

ENSG00000182256

GABRG3

ENSG00000182256

GABRG3

PAX9

ENSG00000198807

ENSG00000182256

PAX9

ENSG00000198807

21

19

16

16

16

16

15

15

15

15

15

15

15

14

14

38,967,270

6,847,380

77,748,399

77,729,566

77,702,883

77,109,437

25,403,913

25,325,462

25,000,416

24,974,470

24,955,101

24,905,945

24,900,346

36,515,956

36,507,279

0.0026

0.0017

0.0088

0.0038

0.0060

0.0081

0.0017

0.0099

0.0064

0.0035

0.0020

0.0057

0.0071

0.0079

0.0020

0.0051

0.0012

0.02

0.0013

0.03

0.04

0.0063

0.04

0.02

0.0091

0.0045

0.02

0.0064

0.03

0.0072

1.88 (1.24-2.85)

0.31 (0.14-0.67)

2.06 (1.19-3.57)

1.70 (1.18-2.43)

2.85 (1.31-6.22)

0.49 (0.29-0.84)

0.60 (0.43-0.82)

2.02 (1.17-3.46)

1.59 (1.14-2.22)

1.59 (1.16-2.16)

1.68 (1.21-2.34)

1.58 (1.14-2.19)

0.60 (0.41-0.87)

2.30 (1.23-4.33)

0.43 (0.25-0.75)
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A

ERG
RASD2
RASD2

ENSG00000157554

ENSG00000100302

ENSG00000100302

22

22

21

34,243,552

34,235,013

38,978,129

0.0037

0.0030

0.0027

Positions refer to NCBI36 (hg18, March 2006 assembly) build of the human genome.

SNP_A2019255
SNP_A1876025
SNP_A8549971
0.0089

0.0034

0.0053

1.58 (1.16-2.15)

1.62 (1.18-2.24)

1.87 (1.24-2.83)

100

48,945,764
48,946,762
48,949,643
48,951,522
48,954,639
48,967,735
48,968,088
49,043,425
49,044,545
49,062,612
49,098,912
49,141,487
49,141,564
49,145,845
49,145,866

SNP

rs10174620
rs10490128
rs1558604
rs13418054
rs10186748
rs9789744
rs9789406
rs6166
rs6165
rs1007540
rs3788982
rs11686474
rs11680730
rs12473870
rs12473815

Location
within
gene
3'
3'
3'
3'
3'
3'
3'
exon 10
exon 10
intron 8-9
intron 3-4
intron 2-3
intron 2-3
intron 2-3
intron 2-3
C

C

0.80
0.91
0.60
0.34
0.77
0.34
0.22
0.56
0.66
0.04
0.36E
0.25E
0.22E
0.12E
0.25E

0.60
0.66
0.59
NAC
0.32
0.17
0.88
0.43
0.41
0.61
0.36E
0.03E
0.02E
0.03E
0.02E
E

0.65
0.64
0.33
NAC
0.38
0.83
0.66
0.68
0.29
0.69
0.17E
0.008E
0.004E
0.006E
0.003D,

0.94
0.99
0.81
0.66
0.87
0.65
0.43
0.50
0.86
0.05
0.38E
0.08E
0.06E
0.18E
0.05E

0.008B
0.004
0.003D
0.15
0.004
0.002D
0.28
0.38
NAC
0.54
0.001D
9.92x10-4 D
0.001D
0.001D
0.002D
0.009
0.002D
0.003D
0.05
0.004
6.78 x10-4 D
0.12
0.49
NAC
0.37
3.94 x10-4 D
2.72 x10-4 D
3.92 x10-4 D
3.38 x10-4 D
6.81 x10-4 D

US Hispanics (73
US Blacks (n=79
cases, 292 controls) cases, 164 controls)
Genotypic Allelic Genotypic Allelic
test
test
test
test

Finnish (n= 165 cases,
163 controls )
Genotypic Allelic test
test
0.50
0.35
0.46
0.48
0.64
0.85
0.18
0.25
0.34
0.25
0.32
0.35
0.66
0.49E
0.60E

0.58
0.49
0.49
0.76
0.53
0.69
0.30
0.49
0.63
0.49
0.09
0.56
0.85
0.77E
0.86E

US Whites (n= 147
cases, 157controls)
Genotypic Allelic
test
test

rs12996690 49,578,470 5'
NA
NA
0.72
0.61
0.79
0.59
0.73
0.85
A
Positions refer to NCBI36 (hg18, March 2006 assembly) build of the human genome.
B
Bolded numbers indicate p-value < 0.01.
C
Marker excluded for failing one or more of the following measures: Hardy-Weinberg Equilibrium failure in controls p<0.001, call
rate <95%, MAF<0.05.
D
Marker significant correcting for 13 M-effective number of tests (p<0.004).
E
Same allele/genotype trends in same direction as Finnish risk-promoting allele.

Position
(bp) A

SNP information

Table 4.4: SNPs in the FSHR gene region tested across Finnish and 3 independent US populations.
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Affymetrix
Probe ID
SNP_A-8453479
SNP_A-8538681
SNP_A-2278783
SNP_A-2214277
SNP_A-4298227
SNP_A-8280065
SNP_A-8574083
SNP_A-1963108
SNP_A-8393579
SNP_A-1826650
SNP_A-8483677
SNP_A-2040656
SNP_A-4297732
SNP_A-1925725
SNP_A-2050457
SNP_A-1963109
SNP_A-2259062
SNP_A-1963110
SNP_A-4208066
SNP_A-8429689
SNP_A-8653066
SNP_A-1801629

rs11680746
rs13001105
rs17037665
rs10174620
rs10187173
rs12614293
rs10490128
rs17556008
rs1558604
rs17037685
rs733726
rs17037700
rs13418054
rs17037707
rs6708130
rs12477968
rs10186748
rs17037739
rs10490127
rs6755046
rs4605416
rs17037744

dbSNP ID

SNP information

48,937,400
48,937,752
48,943,898
48,945,764
48,945,942
48,946,413
48,946,762
48,947,479
48,949,643
48,949,886
48,950,339
48,950,558
48,951,522
48,951,679
48,952,201
48,954,153
48,954,639
48,963,807
48,963,897
48,965,520
48,965,818
48,966,005

A

Location (bp)

Allelic test pvalue
0.005B
0.45
0.62
0.009
0.03
0.41
0.002
0.007
0.003
0.32
0.57
0.44
0.05
0.002
0.03
0.32
0.004
0.02
0.04
0.02
0.02
0.01

Odds ratio
(95% CI)
0.47 (0.27-0.81)
1.13 (0.82-1.55)
0.87 (0.49-1.52)
0.59 (0.40-0.88)
0.71 (0.52-0.96)
0.85 (0.58-1.25)
0.54 (0.36-0.8)
0.36 (0.16-0.78)
1.60 (1.17-2.20)
0.77 (0.45-1.30)
0.86 (0.52-1.44)
0.80 (0.45-1.42)
0.65 (0.42-1.01)
0.43 (0.25-0.75)
0.62 (0.40-0.96)
0.77 (0.45-1.30)
1.58 (1.15-2.17)
1.48 (1.05-2.09)
0.64 (0.42-0.99)
0.58 (0.37-0.90)
0.58 (0.37-0.91)
0.56 (0.36-0.89)

Genotypic
test p-value
0.008
0.73
0.36
0.008
0.07
0.61
0.004
0.03
0.003
0.21
0.21
0.35
0.15
0.006
0.09
0.21
0.004
0.04
0.12
0.04
0.05
0.04

Preterm birth affection status
(n= 165 cases, 163 controls )

0.04
0.69
0.23
0.01
0.008
0.62
0.002
0.03
0.001
0.06
0.28
0.14
0.04
0.03
0.02
0.06
0.004
0.02
0.02
0.003
0.003
0.003

QT p-value

Gestational
age
(n=294)

0.33
0.95
0.25
0.10
0.37
0.83
0.12
0.04
0.57
0.24
0.22
0.55
0.84
0.35
0.90
0.24
0.54
0.98
0.87
0.85
0.82
0.81

QT p-value

Birthweight
Z-score
(n=208)

Table 4.5: Comparison of association results for SNPs in the FSHR gene region in Finnish mothers for the binary phenotype
preterm birth affection status and quantitative phenotypes gestational age and birthweight Z-score.
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SNP_A-8574085
SNP_A-8693449
SNP_A-8465993
SNP_A-2089520
SNP_A-2144280
SNP_A-8371345
SNP_A-8294098
SNP_A-1963111
SNP_A-1963112
SNP_A-4261919
SNP_A-2234736
SNP_A-2031669
SNP_A-1899686
SNP_A-8610973
SNP_A-8498619
SNP_A-8424745
SNP_A-8702492
SNP_A-2209987
SNP_A-2095708
SNP_A-1949646
SNP_A-8402315
SNP_A-8314084
SNP_A-8372663
SNP_A-8480826
SNP_A-8678552
SNP_A-1816022
SNP_A-8308066
SNP_A-2258053
AFFXSNP_9110811

rs10490126
rs9789744
rs9789406
rs2110571
rs2110570
rs981273
rs4953637
rs10490124
rs10490123
rs2215912
rs7563889
rs7565910
rs4952929
rs17038295
rs1922479
rs6545082
rs2349411
rs4953644
rs12991538
rs989373
rs7565565
rs1024777
rs17037887
rs6706144
rs4952932
rs2160149
rs6545085
rs4140979
rs4140979

48,967,652
48,967,735
48,968,088
48,969,725
48,969,746
48,974,053
48,976,209
48,977,978
48,978,206
48,978,309
48,983,394
48,988,842
48,992,854
48,995,342
49,000,591
49,007,179
49,008,184
49,008,904
49,009,151
49,011,829
49,018,596
49,019,982
49,022,712
49,024,081
49,028,586
49,031,882
49,034,975
49,036,913
49,036,913

0.05
6.78 x10-4
0.12
0.19
0.13
0.67
0.14
0.10
0.48
0.48
0.19
0.09
0.91
0.74
0.26
0.24
0.43
0.47
0.40
0.55
0.82
0.93
0.33
0.26
0.67
0.26
0.98
0.39
0.48

0.65 (0.42-1.00)
0.56 (0.40-0.78)
1.33 (0.93-1.91)
0.81 (0.60-1.11)
1.32 (0.92-1.88)
1.10 (0.70-1.73)
0.79 (0.58-1.08)
1.75 (0.89-3.44)
0.83 (0.50-1.39)
0.83 (0.50-1.39)
1.55 (0.80-3.03)
0.76 (0.56-1.04)
1.02 (0.74-1.40)
1.09 (0.66-1.79)
1.20 (0.87-1.65)
1.26 (0.86-1.84)
0.85 (0.57-1.27)
0.78 (0.40-1.53)
0.80 (0.48-1.35)
1.10 (0.80-1.52)
0.97 (0.71-1.31)
1.01 (0.75-1.38)
0.78 (0.46-1.30)
0.76 (0.48-1.22)
0.93 (0.68-1.28)
1.22 (0.87-1.70)
1.00 (0.73-1.39)
1.16 (0.83-1.61)
1.13 (0.81-1.56)

0.14
0.002
0.28
0.40
0.32
0.68
0.26
0.07
0.16
0.16
0.14
0.21
0.99
0.93
0.35
0.49
0.09
0.55
0.13
0.80
0.23
0.14
0.11
0.27
0.76
0.51
0.91
0.07
0.09

0.03
0.001
0.01
0.26
0.04
0.86
0.12
0.92
0.76
0.76
0.85
0.12
0.67
0.66
0.77
0.93
0.70
0.82
0.66
0.90
0.75
0.61
0.58
0.23
0.73
0.07
0.74
0.86
0.77

0.94
0.75
0.88
0.35
0.41
0.49
0.16
0.33
0.33
0.33
0.25
0.12
0.98
0.03
0.04
0.51
0.46
0.09
0.18
0.23
0.90
0.89
0.18
0.53
0.36
0.90
0.05
0.09
0.10
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SNP_A-2117142
SNP_A-1963114
SNP_A-1849765
SNP_A-8656117
SNP_A-8671693
SNP_A-8301277
SNP_A-2150730
SNP_A-8570896
SNP_A-8589739
SNP_A-1875185
SNP_A-2181014
SNP_A-8557127
SNP_A-8588997
SNP_A-8401244
SNP_A-4261920
SNP_A-1963115
SNP_A-2131602
SNP_A-8574090
SNP_A-8574091
SNP_A-8574092
SNP_A-8294822
SNP_A-8632763
SNP_A-2191583
SNP_A-8687005
SNP_A-1916373
SNP_A-1963116
SNP_A-1963117
SNP_A-1963118
SNP_A-4261921
SNP_A-2242483

rs1861168
rs1882559
rs6166
rs2058595
rs4953650
rs8179692
rs2072489
rs6705106
rs4953652
rs2284674
rs7594937
rs2268363
rs6545091
rs2268361
rs989359
rs1922472
rs2268359
rs2300437
rs1007541
rs1007540
rs3788985
rs2072486
rs13002977
rs10186089
rs13031735
rs1922466
rs1922465
rs6746533
rs6732220
rs1922463

49,037,518
49,041,818
49,043,425
49,045,094
49,045,243
49,046,208
49,048,913
49,051,684
49,052,016
49,054,317
49,054,636
49,054,832
49,054,957
49,055,116
49,055,989
49,056,089
49,058,614
49,060,997
49,062,538
49,062,612
49,066,013
49,071,420
49,072,538
49,072,628
49,072,827
49,073,584
49,073,612
49,076,076
49,076,376
49,078,084

0.65
0.95
0.49
0.96
0.97
0.74
1.00
0.19
0.60
0.79
0.35
0.21
0.70
0.43
0.70
0.86
0.69
0.76
0.36
0.37
0.86
1.00
0.60
0.36
0.80
0.73
0.60
0.60
0.72
0.51

0.93 (0.68-1.27)
1.02 (0.63-1.64)
0.90 (0.66-1.22)
1.01 (0.73-1.39)
0.99 (0.72-1.38)
0.95 (0.70-1.29)
1.00 (0.62-1.62)
1.25 (0.89-1.76)
0.87 (0.52-1.46)
0.95 (0.66-1.37)
0.80 (0.50-1.28)
0.76 (0.50-1.17)
1.08 (0.74-1.55)
0.88 (0.64-1.21)
1.08 (0.74-1.55)
0.97 (0.68-1.38)
0.92 (0.60-1.41)
0.93 (0.57-1.51)
0.82 (0.54-1.25)
0.83 (0.56-1.25)
0.95 (0.56-1.62)
1.00 (0.74-1.36)
0.92 (0.67-1.26)
0.82 (0.54-1.25)
0.96 (0.69-1.32)
0.95 (0.69-1.30)
0.92 (0.67-1.26)
0.92 (0.67-1.26)
0.94 (0.66-1.33)
0.90 (0.65-1.23)

0.37
0.80
0.38
0.07
0.09
0.68
0.82
0.40
0.80
0.57
0.05
0.02
0.38
0.69
0.38
0.61
0.91
0.13
0.64
0.54
0.14
0.27
0.84
0.64
0.97
0.93
0.84
0.87
0.50
0.56

0.77
0.85
0.74
0.87
0.65
0.72
0.81
0.13
0.57
0.95
0.17
0.04
0.54
0.34
0.56
0.97
0.33
0.39
0.16
0.87
0.23
0.75
0.24
0.16
0.67
0.26
0.24
0.26
0.52
0.13

0.64
0.06
0.61
0.02
0.03
0.58
0.04
0.57
0.03
0.49
0.65
0.93
0.61
0.90
0.42
0.50
0.02
0.84
0.10
0.37
0.99
0.71
0.48
0.10
0.35
0.50
0.48
0.39
0.63
0.51
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SNP_A-8437573
SNP_A-4232093
SNP_A-1957741
SNP_A-8327608
SNP_A-8323502
SNP_A-8399688
SNP_A-1855471
SNP_A-8326035
SNP_A-1963120
SNP_A-1944026
SNP_A-8588395
SNP_A-8604497
SNP_A-1872622
SNP_A-8320178
SNP_A-8574093
SNP_A-8574094
SNP_A-8574095
SNP_A-8335818
SNP_A-1963123
SNP_A-8431533
SNP_A-2197501
SNP_A-2065169
SNP_A-1863973
SNP_A-2143695
SNP_A-1795584
SNP_A-2165293
SNP_A-1963125
SNP_A-1963126
SNP_A-2119506
SNP_A-2187829

rs3788983
rs3788982
rs3788981
rs1882558
rs2349415
rs1504187
rs4246578
rs12713033
rs10495962
rs17038087
rs10171892
rs13008999
rs13009588
rs13009434
rs17038094
rs1910566
rs6741370
rs6545092
rs6545094
rs17038105
rs1277459
rs10865238
rs12465332
rs17038116
rs12614817
rs3850344
rs1504175
rs1857706
rs11686474
rs11680730

49,098,768
49,098,912
49,099,065
49,101,241
49,101,336
49,103,279
49,103,424
49,104,325
49,108,935
49,111,262
49,111,371
49,112,242
49,112,333
49,112,485
49,112,894
49,117,774
49,119,336
49,119,389
49,119,818
49,120,251
49,120,697
49,122,308
49,122,889
49,122,975
49,124,921
49,126,316
49,131,327
49,131,455
49,141,487
49,141,564

0.02
3.94 x10-4
0.04
0.88
0.40
0.20
0.06
0.97
0.13
0.10
0.35
0.65
0.65
0.57
0.46
0.73
8.08 x10-5
0.21
0.28
0.08
0.08
0.04
0.43
0.01
0.006
0.07
5.98 x10-4
0.07
2.72 x10-4
3.92 x10-4

0.66 (0.48-0.93)
2.36 (1.45-3.84)
0.72 (0.53-0.99)
1.02 (0.74-1.41)
0.87 (0.63-1.21)
0.81 (0.58-1.12)
0.58 (0.33-1.03)
1.01 (0.73-1.38)
1.35 (0.92-1.98)
1.38 (0.94-2.03)
0.86 (0.62-1.18)
1.08 (0.78-1.49)
1.08 (0.78-1.49)
1.10 (0.80-1.51)
1.15 (0.80-1.65)
1.06 (0.77-1.44)
2.35 (1.53-3.63)
0.82 (0.61-1.12)
0.84 (0.62-1.15)
0.61 (0.35-1.07)
0.71 (0.48-1.04)
0.71 (0.52-0.98)
1.14 (0.83-1.57)
0.52 (0.31-0.86)
0.64 (0.47-0.88)
0.74 (0.54-1.02)
0.58 (0.43-0.79)
0.66 (0.43-1.04)
1.82 (1.32-2.52)
1.80 (1.30-2.49)

0.06
0.001
0.09
0.87
0.03
0.29
0.19
0.99
0.29
0.24
0.25
0.78
0.78
0.78
0.43
0.88
6.44 x10-4
0.19
0.22
0.24
0.19
0.02
0.60
0.04
0.02
0.06
0.003
0.11
9.92 x10-4
0.001

0.02
0.008
0.06
0.64
0.25
0.12
0.39
0.97
0.09
0.07
0.28
0.80
0.80
0.71
0.30
0.74
0.001
0.48
0.56
0.46
0.04
0.03
0.67
0.11
0.009
0.05
0.006
0.54
0.004
0.007

0.25
0.57
0.20
0.02
0.28
0.98
0.54
0.006
0.38
0.48
0.22
0.01
0.01
0.01
0.43
0.19
0.07
0.02
0.03
0.45
0.35
0.46
0.04
0.75
0.48
0.30
0.63
0.17
0.13
0.16
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SNP_A-8694413
SNP_A-1872585
SNP_A-2006361
SNP_A-8536246
SNP_A-1783559
SNP_A-2132897
SNP_A-2226105
SNP_A-4275652
SNP_A-1963128
SNP_A-4261924
SNP_A-8574096
SNP_A-8574097
SNP_A-4208068
SNP_A-8574098
SNP_A-4208069
SNP_A-4208070
SNP_A-1963130
SNP_A-1963131
SNP_A-2199691
SNP_A-4197527
SNP_A-1808513
SNP_A-2171016
SNP_A-1929434
SNP_A-8316753
SNP_A-2081721
SNP_A-1963132
SNP_A-4261925
SNP_A-2248307
SNP_A-1963134
SNP_A-2132947

rs12473870
rs12473815
rs6724851
rs12622212
rs1604821
rs2349711
rs12052611
rs974895
rs974896
rs17772297
rs1504174
rs6760923
rs10495964
rs9309159
rs17038275
rs10495965
rs10495966
rs17038285
rs4971642
rs10199118
rs10211458
rs17038315
rs12477795
rs1553474
rs17038320
rs1157876
rs1504182
rs1504183
rs953547
rs4500983

49,145,845
49,145,866
49,149,900
49,153,738
49,156,576
49,160,796
49,170,652
49,184,334
49,184,353
49,184,796
49,186,728
49,194,560
49,195,505
49,195,556
49,195,570
49,196,308
49,196,425
49,196,505
49,196,676
49,207,442
49,207,498
49,210,919
49,211,178
49,213,180
49,219,551
49,223,862
49,227,443
49,227,555
49,230,415
49,239,003

3.38 x10-4
6.81 x10-4
0.05
0.17
0.08
0.12
0.04
0.001
5.94 x10-4
0.001
0.13
0.006
0.65
0.44
0.22
0.79
0.72
0.72
0.02
0.72
0.65
0.006
0.96
0.19
0.009
0.85
0.09
0.005
0.02
0.11
1.82 (1.31-2.52)
1.76 (1.27-2.45)
1.36 (1.00-1.86)
1.31 (0.89-1.94)
1.33 (0.97-1.81)
1.28 (0.94-1.74)
1.38 (1.01-1.87)
1.97 (1.31-2.97)
1.75 (1.27-2.41)
1.97 (1.31-2.98)
0.71 (0.46-1.10)
1.82 (1.18-2.82)
0.92 (0.65-1.31)
1.14 (0.82-1.57)
0.71 (0.41-1.23)
0.95 (0.67-1.35)
0.94 (0.66-1.33)
0.94 (0.66-1.33)
1.70 (1.10-2.63)
0.94 (0.66-1.33)
0.92 (0.65-1.31)
1.82 (1.18-2.82)
1.01 (0.70-1.45)
1.33 (0.87-2.04)
1.77 (1.15-2.73)
0.97 (0.69-1.36)
1.30 (0.96-1.77)
1.86 (1.20-2.90)
1.45 (1.06-2.00)
1.29 (0.94-1.75)
0.001
0.002
0.09
0.38
0.17
0.26
0.12
0.004
0.003
0.004
0.31
0.009
0.85
0.57
0.49
0.94
0.91
0.91
0.04
0.91
0.85
0.02
0.99
0.40
0.03
0.81
0.18
0.02
0.03
0.22

0.006
0.01
0.05
0.57
0.10
0.14
0.04
0.004
0.005
0.004
0.41
0.010
0.64
0.69
0.55
0.71
0.71
0.71
0.02
0.71
0.65
0.007
0.94
0.65
0.01
0.98
0.11
0.02
0.04
0.14

0.27
0.29
0.15
0.05
0.14
0.03
0.45
0.24
0.64
0.32
0.69
0.50
0.38
0.45
0.67
0.38
0.38
0.38
0.43
0.38
0.38
0.50
0.92
0.59
0.43
0.67
0.18
0.49
0.40
0.15
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B

A

rs10495963
rs6761392
rs13428062
rs1032838
rs13019040
rs972557
rs1504155
rs11125217

49,244,517
49,246,886
49,248,239
49,253,850
49,254,126
49,254,706
49,255,754
49,260,940

0.33
0.29
0.58
0.22
0.26
0.28
0.21
0.31

1.21 (0.83-1.76)
1.18 (0.87-1.61)
0.89 (0.59-1.34)
0.81 (0.58-1.14)
0.83 (0.61-1.14)
0.84 (0.62-1.15)
0.82 (0.61-1.12)
0.84 (0.61-1.17)

Positions refer to NCBI36 (hg18, March 2006 assembly) build of the human genome.
Bolded numbers indicate p-value < 0.01.

SNP_A-1963135
SNP_A-8608826
SNP_A-8466163
SNP_A-1963136
SNP_A-8584561
SNP_A-1963137
SNP_A-1963138
SNP_A-8430734

0.62
0.53
0.59
0.48
0.32
0.51
0.31
0.57

0.45
0.16
0.55
0.16
0.06
0.04
0.04
0.12

0.46
0.47
0.81
0.61
0.44
0.21
0.16
0.48

Chapter 5: Association of cystolic phospholipase A2 gamma, PLA2G4C, with PTB risk**

Abstract
Correlating differences in genomic sequences with differences in reproductive
physiology across species may led to new insights into mechanisms underlying birth
timing. PLA2G4C, a phospholipase A isoform involved in prostaglandin synthesis,
emerged from a comparative genomics screen of highly conserved noncoding elements as
rapidly evolving in humans. Detailed structural and phylogenic analysis of PLA2G4C
suggested a short genomic element within the gene duplicated from a paralogous highly
conserved element on chromosome 1 specifically in primates. To examine whether this
gene demonstrating primate-specific evolution was associated with birth timing, we
genotyped common variation in PLA2G4C in US Hispanic (n= 73 preterm, 292 control),
US White (n= 147 preterm, 157 control) and US Black (n= 79 preterm, 166 control)
mothers. SNPs rs8110925 and rs2307276 in US Hispanics and rs11564620 in US Whites
were significant after correcting for multiple tests (p<0.004). Additionally, rs11564620
(Thr360Pro) was associated with increased metabolite levels of the prostaglandin
thromboxane in healthy individuals (p=0.02), suggesting this variant may affect
PLA2G4C activity. Association findings suggest variation in PLA2G4C gene may
influence PTB risk by increasing levels of prostaglandins, which are known to regulate
labor.

**

This chapter is adapted from: Plunkett J, et al. Primate-specific evolution of noncoding
element insertion into PLA2G4C and human preterm birth. In preparation.
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Introduction
A growing body of evidence supports genetic influences on PTB risk; however,
few genes have been consistently associated with the disorder [179; 180]. Investigators
have typically focused on candidate genes selected based on predicted parturition
physiology; however, this approach may be limited by the divergence in physiological
mechanisms between humans and model organisms that have been typically studied. For
example, while a rapid decline in progesterone plays a prominent role in initiating
parturition in rodents and sheep, this signal does not seem to precede human labor [181].
Other parturition-related traits, such as placental morphology and source of progesterone,
also differ importantly in humans compared to model organisms typically studied and
may limit what generalizations can be made [181].
Differences in parturition physiology between apes, including humans, and other
mammals may have developed in response to uniquely human adaptations including
relatively large human head size and narrow birth canal cross-sectional area [127]. Genes
involved in parturition likely have evolved differentially along the human and/or higher
primate phylogenetic lineages to decrease the length of gestation and alleviate the
complications arising from these constraints. As a result, the set of genes rapidly evolving
on the human and/or higher primate lineage likely includes genes that play important
roles in regulating parturition and potentially influence PTB risk. Consistent with our
hypothesis, we identified FSHR as rapidly evolving by nucleotide substitution and as
associated with PTB risk across independent populations [136].
In addition to nucleotide substitution, genomic rearrangements account for an
important portion of genomic divergence among species. For example, Frazer et al. [182]
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and Wetterbom et al. [183] observed insertions and deletions frequently when comparing
genome sequences among humans, chimpanzees and other primate species. Moreover,
these rearrangements may account for a larger fraction of genomic divergence than
nucleotide substitutions [183]. Rearrangements can lead to loss or acquisition of exons,
splice sites and promoters, facilitating differences in expression patterns, such as those
observed for transcript variants of CHRM3 and SFTPB with differing transposable
element insertion events [184; 185]. Hence, genomic rearrangement may contribute to
rapid evolution along the human and/or higher primate lineages in response to unique
physiological constraints.
We hypothesize that genes with genomic rearrangements from the ancestral state
occurring on the human and/or higher primate lineages may play important roles in birth
timing and preterm delivery. Here, we examine common variants in a gene, PLA2G4C, in
which we have identified a primate-specific insertion event and whose expression in the
uterus [186] and role in prostaglandin synthesis suggest a potential role in parturition, for
association with PTB.

Results
Evolutionary history of a primate-specific PLA2G4C noncoding element. We
identified genes showing evidence of rapid evolution along the human lineage, based on
evidence from a comparative genomic screen of highly conserved noncoding elements as
described in [136]. Among the rapidly evolving genes emerging from our noncoding
screen, PLA2G4C was identified as the most statistically significant gene (human lineage
p=2.2x10-7, significant at 10% False Discovery Rate threshold) that was also included in
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a list of PTB candidate genes [134]. Because the reported deletion of PLA2G4C in cattle
[187] contrasted with its presence in the 17-way MultiZ alignments [165] we used to
identify the gene as rapidly evolving (Figure 5.1A), we examined the history of this
region in greater depth. We compared sequence surrounding the 130 basepair (bp) highly
conserved noncoding element in intron 14 of PLA2G4C on chromosome 19q13.3, which
strongly motivated the gene’s designation as rapidly evolving along the human lineage, to
other mammalian and primate genomes. From such comparisons, we determined that this
130 bp element on human chromosome 19 was highly similar to a highly conserved
noncoding element on human chromosome 1 (BLASTN 114/130 bp identical (87%),
BLAST expect value= 5x10-38; Figure 5.1B). Subsequent analysis showed the MultiZ
alignments we used in our comparative genomics screen had misaligned the human
chromosome 19 element with sequences in other mammals which were orthologous to
human chromosome 1. When appropriate alignments were examined, we observed that
the human chromosome 19 element was nearly identical in higher primate species
(chimpanzee, gorilla, orangutan, macaque) examined, but, absent in syntenic sequences
in lower primates (lemur, bushbaby, tarsier) and other mammalian species. Chromosome
1 elements from higher primates are more similar to lower primates and other
mammalian species than chromosome 19 elements (Figure 5.2). The chromosome 1
element occurs in the 5’ untranslated region of RNF11, a gene involved in inflammatory
signaling, as it does in mouse. Thus, a duplication of chromosome 1 noncoding element
to chromosome 19 likely occurred before the last common ancestor between apes and
macaque. A phylogenetic tree of coding sequences for PLA2G4C follows the expected
mammalian phylogeny (Figure 5.3), suggesting that the duplication did not include

110

coding sequences. Together these results suggest that neither element would qualify as
rapidly evolving along the human lineage due to nucleotide substitution, but, the
chromosome 19 element may represent a primate-specific change meriting further study.
Association with preterm birth. Because of recent data that suggests heritability
of risk of PTB acts largely or exclusively through the maternal genome [29; 30; 32], we
genotyped US Hispanic (73 preterm, 292 control), US Whites (n= 147 preterm, 157
control) and US Blacks (n= 79 preterm, 166 control) mothers for 14 SNPs in the
PLA2G4C gene region (Table 5.1). The results from these analyses, reported in Table 5.2,
include two SNPs, rs8110925 and rs2307276, in the US Hispanics and one in the US
Whites, rs11564620, that were significant after correcting for 14 tests (p<0.004). The
direction of effect was generally consistent across populations for these SNPs, as noted in
Table 5.2. Meta-analysis p-values for SNPs rs8110925, rs2307276, and rs11564620 were
also statistically significant after correcting for 14 tests (p<0.004; Figure 5.4).
Additionally, 2, 3 and 4 SNP haplotypes containing SNPs rs8110925 and
rs2307276 were significant in the US Hispanics after correcting for 18 haplotype
comparisons (p<0.003), although not more significant than single SNP association
findings (Table 5.3). 2 SNP haplotypes containing rs11564620 were moderately
significant (p<0.05) in US Whites (Table 5.3). Linkage disequilibrium (LD) among SNPs
rs8110925, rs2307276, and rs11564620 was very low (r2<0.1) in the three populations
studied (Figure 5.5), suggesting multiple independent associations were observed.
Association with prostaglandin concentrations. To test the potential functional
effect of associated PLA2G4C variants on prostaglandin metabolism, we compared levels
of metabolites of prostaglandin E2 (PGE), prostaglandin I2 (PGI) and thromboxane (11-

111

DTXB2) among genotype classes for associated SNPs rs8110925, rs2307276, and
rs11564620 in healthy individuals using a two-sided Wald test (Table 5.4). Of note,
rs11564620, a nonsynonymous coding polymorphism, is associated with 11-DTXB2
levels (p=0.04) despite the limited sample size available. The minor allele of rs11564620,
present at approximately 10% frequency in US Whites, is associated with both risk for
PTB and higher 11-DTXB2 levels (Wilcoxon one-sided p=0.02; Figure 5.6).

Discussion
Genomic analysis of PLA2G4C indicated that the conserved element which
brought the gene to our attention was highly similar to a conserved element on human
chromosome 1. Further study suggested that the conserved element on chromosome 1
was duplicated to chromosome 19 along the primate lineage. As a result, human
chromosome 19 noncoding element in intron 14 of PLA2G4C seems to represent a
primate-specific change involving amplification and subsequent divergence rather than a
region of increased nucleotide substitution, per se. We propose this duplicated element
insertion represents a primate-specific change with a potential regulatory role in human
parturition.
Single SNP and haplotype association results implicate the role of SNPs
rs8110925, rs2307276, and rs11564620 in conferring PTB risk (Tables 5.2 and 5.3). The
associated SNPs are located in an 8 kilobase (kb) region of the 3’ end of PLA2G4C, near
the genomic element of interest (Figure 5.7), but show little LD with each other (Figure
5.5) or other SNPs in PLA2G4C documented in the International HapMap Project
database [151]. Of note, Polyphen [188] and SIFT [189] programs predict rs11564620, a
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nonsynonymous polymorphism in exon 13 resulting in a change in amino acid 360 from
threonine to proline, to be possibly damaging to the protein structure. This 8 kb region
also includes coding sequence for aspartic acid 385, one of the three amino acids that
make up the putative active site of the enzyme [190], such that the proline substitution
may alter the active site’s physical conformation. Supporting the potential functional
effect of rs11564620, this polymorphism is associated with 11-DTXB2 levels in healthy
individuals (p=0.02; Figure 5.6), with proline allele carriers having elevated thromboxane
metabolite levels, compared to threonine homozygotes.
PLA2G4C encodes cytosolic phospholipase A2 gamma, which hydrolizes
phospholipids from the cellular membrane to free arachidonic acid, from which
prostaglandins, including prostaglandins D, E, F, I2 (also known as prostacyclin), and
thromboxane A2 are generated. Prostaglandins likely play an important role in
parturition. Pharmacologically, prostaglandins are used to induce abortion, for cervical
ripening and labor induction, and drugs inhibiting prostaglandin synthesis are successful
in preventing preterm labor [191]. Levels of prostaglandins, including thromboxane A2,
are elevated in pregnant compared to non-pregnant women, and in later (36 weeks)
compared to earlier (20, 30 weeks) gestation [192], suggesting a link between
prostaglandin abundance and parturition timing. Prostaglandins may facilitate labor by
several mechanisms. These hormones are known uterotonic agents and also promote
luteolysis and the onset of labor in species that exhibit progesterone withdrawal prior to
birth [193]. Prostaglandins may also facilitate delivery by affecting placenta function,
since thromboxane A2 induces platelet aggregation and acts as a vasoconstrictor [192].

113

Hence, higher prostaglandin levels than expected may initiate parturition prematurely and
lead to preterm delivery.
The PLA2G4C enzyme is the only cytosolic phospholipase A2 family member
that is constitutively associated with the cellular membrane, the site of prostaglandin
synthesis, rather than translocating to the membrane in response to calcium signaling
[186]. Hence, dysregulation of PLA2G4C may alter prostaglandins levels independent of
other parturition signals, such as oxytocin [194], that act via intracellular calcium
signaling. For example, rs11564620 may contribute to a conformational change in the
enzyme’s active site, rendering it more active than usual and leading to increased
synthesis of prostaglandins, as demonstrated by our observation of higher levels of
thromboxane A2 in minor allele carriers for this polymorphism. Moreover, multiple
splice isoforms of PLA2G4C exist, differing in transcript length, presence of certain
exons and overlapping exons with different boundaries (AceView, NCBI,
http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/). As a result, variation in
PLA2G4C may contribute to differences in tissue-specific expression or relative
abundance of various PLA2G4C isoforms, potentially altering function. Further study of
the region encompassing these SNPs, including the genomic element of interest, is
needed to examine the mechanism by which variation in PLA2G4C influences birth
timing.
Specialization within multi-gene families, like the large phospholipase A2 gene
family, can create individualized functions among paralogous genes. For example,
PLA2G4C has a continuous association with the cellular membrane, unlike other
phospholipase A2 genes, potentially differentiating its role in prostaglandin synthesis
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from those of other family members. Genomic variation, such as the element insertion
observed in PLA2G4C, may contribute to gene specialization, as demonstrated by
divergence in PLA2G4C expression patterns in humans versus mice, who lack the
element insertion and express PLA2G4C only in ovary and oocytes [195]. Specialized
genes are potentially better therapeutic targets than gene products with multiple roles
within cell, since pharmaceutically targeting such genes may lead to fewer side effects.
As a result, PLA2G4C may be a useful target for designing novel therapies to prolong
pregnancy and reduce the incidence of PTB.

Material and Methods
Genomic alignments to investigate evolutionary history of PLA2G4C. Noting
the deletion of PLA2G4C reported in the Taurine Cattle genome [187] contrasted with its
presence in the 17-way MultiZ alignments [165] we used to identify the gene as rapidly
evolving (analysis conducted Spring 2007 and presented in [136]), we examined the
history of this region in greater depth. We extracted sequence surrounding the 130 bp
highly conserved noncoding element (human chromosome 19: 48,560,500 -48,560,630;
hg19 genome build) which largely contributed to our designation of PLA2G4C as rapid
evolving along the human lineage. A BLASTN search of the element revealed highly
identical conserved noncoding elements on human chromosomes 1 (87% identity) and 2
(85% identity) (Figure 5.1B). We compared the human chromosome 19 and chromosome
1 sequences to 31 eutherian mammalian genomes using Ensembl Genomic alignments
(accessed September 2009), and ClustalW alignment, and to specific primate genomes
using BLASTN searches of human, chimpanzee, gorilla, orangutan, macaque, and
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bushbaby genomes (accessed September 2009). We then reconstructed history of the
element by creating phylogenies using the neighbor joining with Kimura distances and
maximum likelihood methods with sequences homologous to the human chromosome 19
element (Figures 5.2) and coding sequences homologous to human PLA2G4C (Figure
5.3).
Human subjects. Study subjects were enrolled for genetic analysis by methods
approved by Institutional Review Boards/Ethics Committees at each participating
institution. Informed consent was obtained for all participants. Mothers with PTB were
included if the birth was spontaneous (non-iatrogenic), singleton, had no obvious
precipitating stimulus (trauma, infection, drug use), and was less than 37 weeks (Yale
University; New York University) or 36 weeks (University of Helsinki; University of
Oulu; Centennial Hospital, Nashville, TN) of completed gestation. Control mothers were
included if they delivered two or more children at 37 weeks or later spontaneously.
Healthy volunteers were recruited at Vanderbilt University for studies of prostaglandin
metabolism. DNA from blood or saliva was prepared by standard methods.
Race/ethnicity was assigned by self-report. All specimens were linked with demographic
and medical data abstracted from maternal/neonatal records. DNA from blood or saliva
was prepared by standard methods.
Prostaglandin metabolite levels. For individuals enrolled in the prostaglandin
study, urine was collected by standard methods. Levels of the urinary metabolites of
prostaglandin E (PGE), prostaglandin I (PGI) and thromboxane (11-DTXB2) were
quantified by mass spectrometry and normalized to creatinine levels, an indicator of renal
function, in 44 healthy control individuals of Black, Hispanic or White race (median age
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29, 60% male, 77% White).
Genotyping. We genotyped 14 SNPs spanning the PLA2G4C gene region (Table
5.1) on human chromosome 19 in cohorts of US Hispanics (n= 73 preterm, 292 control
mothers), US Whites (n= 147 preterm, 157 control mothers) and US Blacks (n= 79
preterm, 166 control mothers). For SNP selection, data from the HapMap CEU
population was examined in the Haploview program [177], using tagger and haplotype
block functions, to identify regions of high LD. We selected 1 SNP per haplotype block,
defined using the D’ confidence interval method [178], having the highest minor allele
frequency (MAF) in the CEU population for genotyping. We also included coding SNPs
and SNPs to improve coverage of conserved elements contributing to the gene’s
designation as “rapidly evolving.” This selection scheme resulted in approximately 35%
coverage of the gene region at r2≥0.8. SNPs showing evidence of association in one or
more cohort (p<0.01; n=4) were then genotyped in healthy individuals on whom data on
their concentrations of several prostaglandin metabolites was available to examine
potential functional effects of the variants. All SNPs were genotyped using the Sequenom
iPLEX massARRAY technology (Sequenom, San Diego, CA).
Data Analysis. Data cleaning and analysis was performed with Whole-genome
Association Study Pipeline (WASP) [174] and PLINK [175]. We excluded individuals
based on genotyping quality (<90% call rate) and possible cryptic relatedness and SNPs
based on the following criteria: not in Hardy-Weinberg Equilibrium in controls (p<0.001
2

test), <90% genotype call rate, MAF<0.01). Linkage disequilibrium among SNPs

tested was determined using the Haploview program [177].
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Our analysis considered PTB affection status (i.e. delivery <37 weeks) as a binary
trait, comparing frequencies between case and control groups of alleles and genotypes by
2

test. Sliding windows of 2,3 and 4 SNP haplotypes also were compared between cases

and controls [175]. Meta-analysis of data for significant SNPs was done using the
Mantel-Haenszel method. We corrected for multiple testing using the simpleM method
[176], which estimates the number of independent tests, given the LD relationships
among SNPs, used to obtain a Bonferroni-corrected critical value.
To test the potential functional effect of associated PLA2G4C variants on
prostaglandin metabolism, we examined the levels of PGE, PGI, and 11-DTXB2,
standardized to normal distributions ( =0, =1), as quantitative traits. A Wald test was
performed to compare the mean phenotype between different allele or genotype classes
for associated SNPs. We also tested whether rs11564620 risk-allele carriers had higher
prostaglandin levels than noncarriers, by comparing the 11-DTXB2 value distribution
among genotype classes with box plots and one-sided Wilcoxon nonparametric test
performed in R [158].

118

119

MultiZ alignments used in the noncoding analysis from which we initially identified PLA2G4C as rapidly evolving include sequence
for lower mammals, including cow, in which the gene is absent (A).

A

Figure 5.1A: Genomic alignments suggest PLA2G4C element duplicated from another chromosome.
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A BLASTN search of the element located in PLA2G4C intron 14 (chromosome 19) that led to the gene’s designation as rapidly
evolving by nucleotide substitution revealed highly identical conserved noncoding elements on human chromosomes 1 and 2 (B).

B

Figure 5.1B: Genomic alignments suggest PLA2G4C element duplicated from another chromosome.

Figure 5.2: Phylogeny with sequences homologous to human chromosomes 19 noncoding element.

Species name followed by a number indicates from which chromosome the sequence is derived or by a
letter indicates that multiple copies homologous to the human chromosome 19 noncoding element were
identified for that species. Sequences from lower primates and other mammalian species are more similar
to higher primate sequences orthologous to human chromosome 1noncoding element (indicated in blue)
than sequences orthologous to human chromosome 19 noncoding element (indicated in red). A duplication
of chromosome 1 noncoding element to chromosome 19 likely occurred before the last common ancestor
between apes and macaque.
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Figure 5.3: Phylogeny with coding sequences homologous to human PLA2G4C.

Species name followed by a letter indicates that multiple copies homologous to human PLA2G4C were
identified for that species. Phylogenetic tree of coding sequences follows expected relationships between
species, suggesting that the duplication event of chromosome 1sequence to chromosome 19 did not include
coding sequence.
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Meta-analysis for US Hispanic, US White and US Black SNP association results for rs8110925.

Figure 5.4A: Meta-analysis of significantly associated SNPs in PLA2G4C.
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Meta-analysis for US Hispanic, US White and US Black SNP association results for rs2307276.

Figure 5.4B: Meta-analysis of significantly associated SNPs in PLA2G4C.
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Meta-analysis for US Hispanic, US White and US Black SNP association results for rs11564620.

Figure 5.4C: Meta-analysis of significantly associated SNPs in PLA2G4C.

Figure 5.5: Linkage Disequilibrium among SNPs tested in PLA2G4C.

Linkage disequilibrium among SNPs tested in PLA2G4C for US Hispanics (A), US
Whites (B), and US Blacks (C).
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Figure 5.6: Comparison of thromboxane metabolite levels among rs11564620
genotype classes in healthy control population.

Median thromboxane metabolite levels are significantly greater among risk-allele
carriers, by Wilcoxon one-sided test.
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The gene structure for PLA2G4C is represented by an arrow in which grey rectangles designate 3’ and 5’ untranslated regions and
white rectangles designate coding exons. A red ellipse represents the primate-specific element of interest. Blue stars indicate
rs2307276 and rs8110925, and yellow starburst indicates rs11564620, which is significant after multiple testing correction (p<0.004)
in US Hispanics and US Whites, respectively.

Figure 5.7: Overview of the SNPs tested in the PLA2G4C gene region.

129

SNP
Position a
rs9226
48,551,546
rs11564650
48,556,979
rs2307281
48,558,286
rs1529479
48,558,388
rs8110925
48,563,432
rs2307276
48,565,207
rs1366442
48,569,709
rs11564620
48,571,072
rs7251954
48,583,239
rs11668556
48,591,380
rs156631
48,598,823
rs251684
48,601,454
rs1653554
48,608,472
rs2307279
48,608,598
a
Positions refer to hg19 build of the human genome.
Location within gene
Exon 17 - 3' UTR
Intron 15
Exon 15 - Asp426Asp
Intron 14
Intron 14
Intron 14
Intron 13
Exon 13 - Thr360Pro
Intron 10
Intron 9
Exon 7- Ser203Pro
Exon 6 - Pro170Pro
Intron 3
Exon 3 - Ala38Pro

Table 5.1: SNPs in the PLA2G4C gene region tested in all cohorts.
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Allele p-value
NAb
0.98
NAb
NAb
7.92 x 10-4 a,c
5.45 x 10-3 c
0.01
0.55 e
NAb
0.32
NAb
NAb
0.84
NAb

Genotype p-value
NAb
0.55
NAb
NAb
5.66 x 10-5 c
0.01
0.03
0.63 e
NAb
0.28
NAb
NAb
0.30
NAb

Allele p-value
NAb
0.14
NAb
NAb
0.92
0.87
0.50
6.98 x 10-3
NAb
0.78
NAb
NAb
0.37
0.59

Genotype p-value
NAb
0.19
NAb
NAb
0.59
0.86
0.02
1.03 x 10-3 c
NAb
0.85
NAb
NAb
0.51
0.12

(n= 147 cases, 157 controls)

(n= 73 cases, 292 controls)
Allele p-value
NAb
0.20
NAb
NAb
0.58 d
0.22
0.92 d
0.47 e
NAb
0.55
NAb
NAb
0.44
0.83

Genotype p-value
NAb
0.26
NAb
NAb
0.83 d
0.49
0.94 d
0.36 e
NAb
0.38
NAb
NAb
0.43
0.89

(n= 79 cases, 166 controls)

US Blacks

b

Bolded numbers indicate p-value <0.05.
Marker excluded for failing one or more of the following measures: Hardy-Weinberg Equilibrium failure in controls p<0.001, <90%
call rate, MAF<0.01.
c
Marker significant correcting for 14 tests (p<0.004).
d
Same allele trends in same direction as US Hispanics
e
Same allele trends in same direction as US Whites

a

SNP
rs9226
rs11564650
rs2307281
rs1529479
rs8110925
rs2307276
rs1366442
rs11564620
rs7251954
rs11668556
rs156631
rs251684
rs1653554
rs2307279

US White

US Hispanics

Table 5.2: Case-control association results for SNPs in the PLA2G4C gene region tested across 4 independent populations.

Table 5.3: Case-control association results for 2, 3 and 4 SNP haplotypes in the
PLA2G4C gene region tested across 3 independent US populations.

2-SNP Haplotypes
rs11564650-rs8110925
rs8110925-rs2307276
rs2307276-rs1366442
rs1366442-rs11564620
rs11564620-rs11668556
rs11668556-rs1653554
rs1653554-rs2307279
3-SNP Haplotypes
rs11564650-rs8110925-rs2307276
rs8110925-rs2307276-rs1366442
rs2307276-rs1366442-rs11564620
rs1366442-rs11564620-rs11668556
rs11564620-rs11668556-rs1653554
rs11668556-rs1653554-rs2307279
4-SNP Haplotypes
rs11564650-rs8110925-rs2307276-rs1366442
rs8110925-rs2307276-rs1366442-rs11564620
rs2307276-rs1366442-rs11564620rs11668556
rs1366442-rs11564620-rs11668556rs1653554
rs11564620-rs11668556-rs1653554rs2307279
a

US Hispanics
p-value

US White
p-value

US Blacks
p-value

9.54x10-3 a
6.98x10-5 b
8.82x10-3
0.04
0.25
0.49
NAc

0.10
0.98
0.64
0.03
0.03
0.82
0.47

0.59
0.24
0.64
0.90
0.63
0.42
0.68

9.60x10-4 b
5.79x10-4 b
0.03
0.06
0.31
NAc

0.19
0.84
0.06
0.08
0.09
0.91

0.39
0.50
0.79
0.92
0.30
0.89

3.26x10-3
1.25x10-3 b
0.08

0.24
0.13
0.17

0.67
0.46
0.93

0.08

0.25

0.47

NAc

0.11

0.54

Bolded numbers indicate p-value <0.05.
Haplotype significant correcting for 18 comparisons (p< 2.78x10-3).
c
One or more marker excluded for failing one or more of the following measures: HardyWeinberg Equilibrium failure in controls p<0.001, <90% call rate, MAF<0.01.
b
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a

PGE p-value
0.44
0.50
0.57

Bolded numbers indicate p-value <0.05.

SNP
rs8110925
rs2307276
rs11564620

PGI p-value
0.42
0.75
0.15

TXB2 p-value
0.51
0.80
0.04a

Table 5.4: Association results for associated SNPs (p≤0.01) in the PLA2G4C gene region for the quantitative phenotypes of
PGE, PGI, and TXB2 metabolite levels examined in healthy individuals (n=44).

Chapter 6: Conclusions and future directions
State of preterm birth genetics prior to this work
Despite the important public health consequences of PTB [3; 4], determinants of
human parturition remain largely uncharacterized, making prediction and prevention of
PTB difficult. Genetic studies are one way in which we can attempt to better understand
this disorder. Prior to this work, little work had been done to characterize genetic
influences on PTB comprehensively. For example, while a variety of evidence suggested
that PTB was influenced by complex genetic and environmental factors, no study had
tested genetic and non-genetic models to support this notion explicitly. Additionally, few
specific genes were associated with PTB at the initiation of this work. Importantly, few
studies examined genes outside of the inflammation and infection pathways, limiting the
potential of genetic studies to identify new biology. As a result, we began this work to
describe genetic influences on PTB in greater depth and identify novel genes associated
with this disorder.
Dissertation specific aims
Because the etiology of PTB is complex and likely involves both genetic and
environmental risk factors, developing a model for the genetic influences on PTB may
facilitate gene discovery. As little work had been done to systematically identify a genetic
model for PTB,we used sibling risk estimates and segregation analyses to identify one.
We examined two standard measures of familial aggregation, the sibling risk
ratio, s, and the sibling-sibling odds ratio (sib-sib OR) to test whether siblings of
preterm infants were at higher risk for preterm delivery themselves. Risk to siblings of an
affected individual was elevated above the population prevalence of a given disorder, as
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indicated by

S( S

(95% CI): 4.3 (4.0-4.6)), and above that of siblings of unaffected

individuals, as indicated by the sib-sib OR (sib-sib OR adjusted for known risk factors
(95% CI): 4.2 (3.9-4.5)). These results suggest that the PTB aggregates in families, which
may be explained in part by genetics.
Additionally, we performed segregation analyses to identify the best fitting
genetic model for gestational age, a quantitative proxy for PTB. We performed
segregation analysis for gestational age as a quantitative trait either attributed to the
infant, infant’s gestational age, or to the mother, by averaging the gestational ages at
which her children were delivered, using 96 multiplex preterm families. Additionally, as
pregnancies in which either the mother [10; 13] or father [6; 7] is Black are at increased
risk for preterm delivery, we performed segregation analysis for each phenotype in the
total sample, as well as stratified by Black and White race, to test for heterogeneity
between these two groups. Results from our segregation analyses lend further support to a
genetic component contributing to birth timing since sporadic (i.e. no familial
resemblance) and nontransmission (i.e. environmental factors alone contribute to
gestational age) models are strongly rejected. Moreover, these results corroborate the
conceptualization of PTB as a complex diseases are influenced by a variety of factors,
none necessary and sufficient to cause the disorder itself, in contrast to Mendelian
disorders in which alterations of a single gene can lead to disease. Analyses of gestational
age attributed to the infant support a model in which mother’s genome and/or maternallyinherited genes acting in the fetus are largely responsible for birth timing, with a smaller
contribution from the paternally-inherited alleles in the fetal genome. Additionally,
results from a heterogeneity

2

test comparing race-stratified analyses suggest that
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genetic influences on birth timing may differ between Blacks and Whites. Overall, as
multiple genes in the mother’s genome may explain the bulk of genetic influences on
birth timing and heterogeneity exists among racial groups, future studies to identify
specific genes influencing PTB perhaps will be most fruitful by using large scale studies
of mothers’ genomes and by considering racial composition of the study samples
carefully in their statistical analysis.
We also aimed to discover specific genes associated with PTB using an a priori
method, a screen of genes selected based on an evolutionary-motivated filter, rather than
predicted parturition physiology. Because humans are born developmentally less mature
than other mammals [124; 125], birth timing mechanisms may differ between humans
and model organisms that have been typically studied [126]; as a result,we screened 150
genes, selected because of their rapid evolution along the human lineage, compared to
other mammalian species, rather than our current understanding of parturition. An initial
screen of over 8000 SNPs in 165 preterm and 163 Finnish mothers identified an
enrichment of variants in FSHR associated with PTB and prompted further study of the
gene. Additionally, the phospholipase gene, PLA2G4C, was examined in greater depth, as
it was identified as the gene with the most statistically significant evidence for rapid
evolution that was also included in a list of PTB candidate genes [134]. Several variants
in PLA2G4C showed potential association and were considered for follow-up analysis.
To validate our initial findings,we examined 74 variants showing moderate levels
of association in Finnish mothers in three additional US populations. Three SNPs in
PLA2G4C and one SNP in FSHR were statistically significant after correcting for the
number of independent tests performed for each gene. Meta-analysis p-values for these
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variants were also significant correcting for multiple comparisons, supporting the role of
PLA2G4C and FSHR in PTB.
Additional work to identify variants in these genes with functional effects was
also initiated. First, we compared metabolite levels of three important downstream targets
of PLA2G4C among genotype classes for significantly associated SNPs in healthy
controls. The nonsynonymous SNP rs11564620 (Thr360Pro) was associated with levels
of the prostaglandin thromboxane, suggesting this variant may affect PLA2G4C activity.
Secondly, because the robustly associated SNP in FSHR was intronic and unlikely to
have a direct effect on function, we initiated sequencing of coding and highly conserved
non-coding regions in the gene in Finnish preterm and control mothers to identify
additional variants, which may have functional effects.
Together, these experiments better characterize the nature of genetic influences on
PTB and provide evidence for novel genes involved in this disorder.
Future directions
While two novel genes have been associated with PTB as the result of this
dissertation project, additional work will be needed to dissect the genetic underpinnings
of PTB robustly and apply this new knowledge towards improved patient care. Such
work may include identifying additional variants in FSHR and PLA2G4C and
determining the ability of highly associated SNPs to predict PTB. Because this work has
examined only common variants, investigating rare variants may be particularly
enlightening. Rare variants tend to have stronger effects on phenotype and may underlie
associations attributed to common variants [196]. A single rare variant or a combination
of multiple rare variants in FSHR, PLA2G4C or other genes may contribute to PTB risk,
as has been shown for other common diseases, like type 1 diabetes and obesity [197];
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thus, whole exome or targeted sequencing may identify risk-promoting variants in FSHR
and PLA2G4C, and additional genes involved in PTB. For genetic variants of interest,
gravid women may be followed prospectively to compare the pregnancy histories
between women with high risk and low risk genotypes. Further study of the proteins
encoded by FSHR and PLA2G4C will also be important to understand the biological
mechanism by which these genes influence PTB risk. In addition to extensions of our
work on PTB, the evolutionarily-motivated approach we used to identify FSHR and
PLA2G4C also may be applied to other traits that differ between humans and other
mammalian species, such as neurological and language-related traits, to assist gene
discovery.
Alternative approaches may also be used to identify additional genes associated
with PTB. Unbiased genome-wide screens, such as the case-control screen conducted on
a Danish cohort as part of the National Institutes of Health Gene Environment
Association Studies (GENEVA) program, may identify novel genes and pathways for
birth timing, as for other complex disorders like type 2 diabetes [198]. Additionally, nonadditive genetic effects, such as copy number or structural variation, may be important
avenues for future research. Moreover, because complex disorders likely depend on a
number of interacting factors, including genetic, epigenetic and environmental risk
factors [31], some polymorphisms may only increase risk in the context of other genetic
polymorphisms or certain environmental factors; as a result, considering polymorphisms
in multiple genes or gene-environment interactions may increase our power to detect
genetic effects. Investigators have applied this approach in candidate gene studies of
PTB, including two studies of IL6 found association with the gene and disorder only in
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the presence of bacterial vaginosis [35] or microbial invasion of intra-amniotic cavity
[37]. Similarly, a study found interactive effects for TNF x IL6 x IL6R, but no main
effects for any of the genes [34]. As a result, testing for gene-gene and gene-environment
interactions globally may improve our ability to discover novel PTB genes. Such
approaches may enable investigators to identify novel genes and pathways involved in
birth timing with important clinical applications.
Overall, future studies to understand genetic influences on PTB likely will include
identifying additional genes and specific variants associated with risk and followed with
work to examine biological mechanisms for their involvement in birth timing. In the
same way that the study of other complex disorders has affected the field of PTB
genetics, the evolutionarily-motivated approach for prioritizing genes for inclusion in
association studies we used to identify FSHR and PLA2G4C may be extended to other
complex traits.
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